,Outcome Measures,count,enrolled
0,Safety (adverse events),13,250
1,Number of cured patients|Number of patients with treatment-related adverse events,5,87
2,Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.,3,27
3,Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease,3,100
4,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement,2,9
5,nan,2,18
6,Adverse Events,2,25
7,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Vancouver Burn Scar Scale,2,35
8,Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS),2,120
9,number of patients cured,2,37
10,Peak Systolic Velocity without trimix (cm/s)|End Diastolic Velocity without trimix (cm/s),2,13
11,Safety and tolerability as measured by incidence of IP-related serious adverse events,2,46
12,Safety of injected exosomes|clinical Efficacy of injected exosomes|inflammatory markers,2,160
13,Incidence of Adverse Events|Changes in 24h urine protein quantification before and after treatment；|Changes in eGFR before and after treatment;|Changes in SLEDAI score before and after treatment；,1,16
14,OSSM-001 (100M dose) related adverse events as assessed by CTCAE v5.0|OSSM-001 (300M dose) related adverse events as assessed by CTCAE v5.0|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (100M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (100M dose)|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (300M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (300M dose),1,16
15,Incidence of adverse events by subconjunctival injection of BMMSCs|Incidence of corneal perforation rate after subconjunctival injection of BMMSCs|Time of corneal epithelialization|Visual acuity,1,16
16,Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment,1,18
17,"Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24",1,16
18,tensile strength of posterior cruciate ligament|Thrombosite of Growth Factor - beta 1|basic fibroblast of growth factor,1,16
19,Safety measured by incidence of serious adverse events|Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment,1,16
20,Number of Serious Adverse Events|Changes in the faecal incontinence diary|Anorectal manometry|Jorge-Wexner Score|Faecal Incontinence Quality of Life,1,16
21,Number of adverse events|Crohn's disease activity Index (CDAI),1,16
22,Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)|Percentage of participants achieving ACR20 from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR50 response from Baseline at Week 12 and Week 24|Percentage of participants achieving ACR70 response from Baseline at Week 12 and Week 24|Change from Baseline in the disease activity score 28-joint count using C reactive protein (DAS28-CRP) at Week 12 and Week 24|Change from Baseline in the health assessment questionnaire disability index (HAQ-DI) score at Week 12 and Week 24|Percentage of participants achieving remission by Simplified Disease Activity Index (SDAI) based criteria at Week 12 and Week 24|Change from Baseline of rheumatoid factor at Week 12 and Week 24|Change from Baseline of anti-cyclic citrullinated peptide (anti-CCP) at Week 12 and Week 24,1,16
23,Neurophysiological parameters - Combined evoked potentials|Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events,1,18
24,Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100,1,16
25,Severity and incidence of adverse events (SIAE) on the day of treatment|3rd day SIAE|1 week SIAE|1 month SIAE|3 months SIAE|6 months SIAE|12 months SIAE|24 months SIAE|RQLQ score|VAS score|Nasal function test|Nasal endoscopy|U-HCG|Detection of Serum Interferon γ (IFN-γ)|Detection of Serum Interferon α (IFN-α)|Detection of Serum Interleukin 1β (IL-1β)|Detection of Serum Interleukin 2 (IL-2)|Detection of Serum Interleukin 4 (IL-4)|Detection of Serum Interleukin 5 (IL-5)|Detection of Serum Interleukin 6 (IL-6)|Detection of Serum Interleukin 8 (IL-8)|Detection of Serum Interleukin 10 (IL-10)|Detection of Serum Interleukin 12P70 (IL-12P70)|Detection of Serum Interleukin 17A (IL-17A)|Detection of Serum Tumor necrosis factor-α（TNF-α）|Detection of inflammatory factor Interferon γ (IFN-γ) in nasal secretions|Detection of inflammatory factor Interferon α (IFN-α) in nasal secretions|Detection of inflammatory factor Interleukin 1β (IL-1β) in nasal secretions|Detection of inflammatory factor Interleukin 2 (IL-2) in nasal secretions|Detection of inflammatory factor Interleukin 4 (IL-4) in nasal secretions|Detection of inflammatory factor Interleukin 5 (IL-5) in nasal secretions|Detection of inflammatory factor Interleukin 6 (IL-6) in nasal secretions|Detection of inflammatory factor Interleukin 8 (IL-8) in nasal secretions|Detection of inflammatory factor Interleukin 10 (IL-10) in nasal secretions|Detection of inflammatory factor Interleukin 12P70 (IL-12P70) in nasal secretions|Detection of inflammatory factor Interleukin 17A (IL-17A) in nasal secretions|Detection of inflammatory factor Tumor necrosis factor-α（TNF-α） in nasal secretions,1,18
26,"Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation.",1,16
27,"Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI.",1,16
28,Number of Treatment Emergent Serious Adverse Events (TE-SAEs)|EPC-CFU Levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels|Tumor Necrosis Factor (TNF) Alpha Levels,1,16
29,Visual Acuity Test|Visual Field Test|Funduscopy|Electrorectinography|Optical Coherence Tomography (OCT)|Angiography,1,18
30,Safety of treatment|Short-time efficacy of treatment,1,16
31,Dose-limiting adverse events/toxicities (DLTs)|OS|Event-free survival|Ventilator-free days|Time to clinical response|Time to hospital discharge,1,18
32,Biochemical Molecular Outcomes|Clinical Outcomes|Imaging Outcomes,1,18
33,Safety evaluation|WOMAC(Western Ontario and McMaster Universities) Index|Magnetic Resonance Imaging|KSCRS(Knee Society Clinical rating System)|VAS(11-point box visual analogue scale)|Histological evaluates,1,18
34,Overall response rate|Progression Free Survival (PFS)|Overall Survival (OS)|Evaluate Safety,1,16
35,PASI score improvement rate|PASI (Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI (Dermatology Life Quality Index),1,16
36,Adverse events|Efficacy-The Wong Baker FACES® pain rating scale|Efficacy-Transcutaneous oxygen pressure(TcPO2)|Efficacy-walking distance (TWD)|Efficacy-Ankle Brachial Pressure Index (ABPI),1,18
37,oxygenation index|The value of arterial blood cLAC|The content of IL-1β|The content of IL-6|The content of TGF-α|The content of HMGB1|The content of IL-10|The content of B-type natriuretic peptide (BNP)|electrocardiogram|The average length of stay in hospital|The visual analog scale（VAS）score|The hospital for special surgery (HSS) Knee Score|The New York Heart Association (NYHA) Functional Classification|The 36-Item Short Form Survey (SF-36)|The Hamilton Anxiety Scale|The incidence of allergic reaction|The body temperature|The pulse rate|The respiration rate|The blood pressure|The content of C-reactive protein (CRP),1,16
38,Epithelial Status Assessment|Visual Acuity|Corneal Epithelial thickness|Corneal Scarring / Haze|Tolerability of MSC secretome drops|Durability of Corneal Epithelial Status Improvement|Time to Improvement of Corneal Epithelial Barrier,1,18
39,Incidence of adverse events|American Spinal Injury Association (ASIA) impairment scale|Motor evoked potentials|Somatosensory evoked potentials|Electrical pain threshold perception|Handgrip Strength|Walking index for spinal cord injury (WISCI II)|Numerical scale for neuropathic pain assessment|Modified Ashworth scale for spasticity|Spinal Cord Independence Measure III (SCIM III)|World Health Organization Quality of life questionnaire (WHOQOL-BREF)|Psychological general well-being index (PGWBI)|Hospital Anxiety and Depression Scale (HADS)|Community Integration Questionaire (CIQ-IG)|AntiHLA antibodies in cerebrospinal fluid (CSF)|Detection of donor cells in CSF,1,18
40,"ETDRS visual acuity:|Visual field sensitivity: Fundus perimetry deviation index (FPDI, %)|Ganglion cell complex thickness (GCC thickness, µm):|Pattern visual evoked potential (pVEP)",1,18
41,Measure of safety one month after first infusion|Change in modified Rodnan skin score (mRss) between Month 0 and Month 12,1,18
42,Tolerance of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection|Dose exploration of patients with idiopathic fibrosis to human umbilical cord mesenchymal stem cell injection|Preliminary efficacy evaluation,1,18
43,Recording of Serious Adverse Events|Functional status of the knee|Quality of life,1,18
44,Recording of Adverse Events and Serious Adverse Events|Electrocardiogram|Vital signs|Physical examination|WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Laboratory tests|SF-36|NRS-11|The volume of articular cartilage,1,18
45,the change of endometrial thickness|pregnancy rate|live birth rate|abortion rate,1,18
46,SPADI(Shoulder pain and disability index)Score|Constant-Murley score|Visual Analog Scale_pain in motion|Changes in the size of rotator cuff tears determined by MRI|Changes in the size of rotator cuff tears determined by arthroscopy|Adverse event,1,18
47,Dose Limiting Toxicity(DLT)|International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)|Response rate of IMACS-TIS|Changes of Core Set Activity Measures(CSAM)|Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Changes of Peak Pruritus Numeral Rating Scale(PPNRS),1,18
48,Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness,1,18
49,Changes in exercise-dependently mobilized stem and progenitor cell numbers in the peripheral blood with antioxidative supplementation|Changes in numbers of exercise-induced apoptotic cells and oxidative stress markers in the peripheral blood with antioxidative supplementation,1,18
50,"Safety: Moderate to severe (including life threatening and death) adverse event occurrences due to product in 1st 52 weeks post procedure|Tolerability: assessed by the proportion of initiated infusion where >80% of the infusion is received by the patient.|Biological activity: Survival with native liver at 24 weeks post treatment.|Change in blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment.|Change in Quality of life measures from baseline to week 52|Patient survival with native liver at 52 weeks post treatment|Patient survival with transplanted or native liver at 24 and 52 weeks post treatment.",1,17
51,Number of participants with adverse side effects.|Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF,1,17
52,Number of patients with tropic ulcers cured|Number of patients with treatment-related adverse events,1,18
53,Improved healing of scarred vocal folds,1,16
54,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in mortality status|Ventilator Free Days (VFD)|Change in Oxygenation Index (OI)|Change in Lung Injury Score (LIS)|Change in positive end-expiratory pressure (PEEP)|Change in Lung Static Compliance|Change in acute physiology and chronic health evaluation score (APACHE II),1,18
55,SAE|Antibodies to HLA Class I - number and percent|Antibodies to HLA Class I - Time To Development|Increase Ulcer Size|Adverse Reaction|Suspected Adverse Reaction|Suspected Serious Adverse Reaction|Change in A1c,1,16
56,Serious adverse events|Serious adverse reactions|Changes of fistula size|Changes in rectovaginal soft tissue density and flexibility|Quality of life monitoring - 1|Quality of life monitoring - 2,1,16
57,Changes of the platelet counts after hUC-MSCs infusion|Incidence of adverse events after hUC-MSCs infusion|Changes in virus safety indicators after hUC-MSCs infusion|Changes of concentration of hUC-MSCs in peripheral blood|Changes of antibody production of hUC-MSCs in peripheral blood|Changes of immune function in refractory ITP patients after hUC-MSCs infusion,1,15
58,EDSS|Annual relapse rate|Lesion load|Retinal nerve fiber layer (RNFL)|Cognition|Immunological assessments|cerebral volume,1,15
59,"The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.",1,15
60,gingival cervicular fluid BMP-2 level|intrabony components (defect bony filling),1,15
61,Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Number of Participants alive by Day 28|Number of Participants with ventilator-free Days by Day 28,1,15
62,Adverse effects at the time of infusion and infections after infusion of MSC|Mesenchymal cell efficiency in recovering cytopenia,1,15
63,Adverse effects|efficacy,1,15
64,Incidence of Serious Adverse Events and Adverse Events,1,15
65,Incidence of Treatment-Emergent and Treatment-Chronic Adverse Events of human umbilical cord mesenchymal stem cells for diabetic nephropathy patient|Changes in eGFR before and after treatment; Changes in 24h urine protein quantification before and after treatment,1,15
66,Total Number of Adverse Events and Serious Adverse Events|The Effect of Single Injection of HB-adMSCs on TNF-a in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on IL-6 in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on CRP in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on ESR in Patients With Acute RA|The Effect of Single Injection of HB-adMSCs on Joint Count in Patients With Acute RA.,1,15
67,"Safety : Observation of at least one adverse effect|Efficacy : Rate of complete or almost complete reepithelialisation|Rate of observed and predicted death by the SCORTEN|Duration of hospitalisation according to our historical cohort related to BSA involved|Duration of hospitalisation according to our historical cohort related to onset of the disease|Duration of hospitalisation according to our historical cohort related to SCORTEN|Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)|Rate of sepsis|Rate of intensive care transfer|Rate of sequelae|Th1/Th2 immune response in the peripheral blood of the patients|Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood|Epidermal chimerism study on healed skin biopsy|Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed.",1,15
68,Comparing the number of side effects and the improvement on ASIA Impairment score between SCI patients receiving autologous AT-MSC vs BM-MSC.|Investigating the number of side effects in SCI patients receiving autologous BM-MSC.|Investigating the effectiveness of autologous BM-MSC in treating SCI patients.|Investigating the number of side effects in SCI patients receiving autologous AT-MSC.|Investigating the effectiveness of autologous AT-MSC in treating SCI patients.,1,14
69,Fistula Closure|Evaluation of perianal disease|Evaluation of Crohn's disease,1,14
70,Adverse Events|Adverse Events (Special Attention Target),1,14
71,"SAE incidences over the study period|SUSAR incidences over the study period|TEAE incidences over the study period|Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.|Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits|Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits|Change and ratios of MRI image from baseline to subsequent scheduled visits|Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits",1,14
72,Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters,1,14
73,Change from baseline in laser flare and cell measurements|Change from baseline in visual function tests,1,14
74,"Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28",1,14
75,Feasibility and safety of bone marrow stem cell transplantation in patients with spinal cord injury|Functional improvement in muscle strength|Improvement of sphincters control.,1,14
76,Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],1,13
77,The number of patients with any relevant side effects observed|Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.,1,13
78,The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03|The reduction ratio of scoring atopic dermatitis (SCORAD) index as contrasted with baseline value|The variation of SCORAD index as contrasted with baseline value|The variation of each index score of SCORAD index as contrasted with baseline value|The variation of the degrees of disease as contrasted with baseline value|The variation of investigator's global assessment (IGA) as contrasted with baseline value|The variation of eczema area and severity index (EASI) total score as contrasted with baseline value|The variation of total immunoglobulin E (IgE) in serum as contrasted with baseline value|The variation of total prostaglandin E2 (PGE2) in serum as contrasted with baseline value|The variation of total eosinophil cationic protein (ECP) in serum as contrasted with baseline value|The variation of total Chemokine ligand 17 (CCL17) in serum as contrasted with baseline value|The variation of total Chemokine ligand 27 (CCL27) in serum as contrasted with baseline value,1,13
79,Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.|Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.,1,13
80,"Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15",1,12
81,"Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI",1,12
82,Dose-Limiting Toxicities rate (DLTs)|Objective response rate|Feasibility of the combination/monotherapy|Incidence of treatment-Emergent Adverse Event|Progression-free survival (PFS)|Overall Survival (OS)|Antiadenoviral humoral immune response in patients|Antiadenoviral tumoral immune response in patients|Replication kinetics of Icovir-5,1,12
83,"Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death",1,12
84,Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM),1,15
85,Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ),1,15
86,"Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation",1,15
87,Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing,1,15
88,Number of Participants with serious and non-serious adverse events|Changes in pulmonary function tests,1,19
89,"Treadmill Walking Distance|VAS(Visual Analog Scale)|Toe-Brachial Pressure Index, TBPI|Transcutaneous oxygen pressure, TcPO2|Arterial Brachial Pressure Index, ABPI|Pain Free Walking Distance, PFWD|Angiography|Laser Doppler|dose and frequency in use of a analgesic medicine|Safety Evaluation",1,15
90,"Primary 1 Safety: rate of (serious) adverse events in the study population 2 Feasibility: determination of the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses|Secondary endpoints: 1 Presence of late acute rejection (in the 6 month biopsy compared with the 4 week biopsy). 2 Sirius red staining for renal cortical matrix accumulation. 3 Immunologic response before and after MSC infusion.",1,15
91,Healing|Health-related quality of life assessed by a disease specific questionnaire|Health-related quality of life assessed by a generic questionnaire,1,15
92,"Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation|Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation|Change baseline Magnetic Resonance Imaging at 6 month after transplantation|The National Institute of Health Stroke Scale (NIHSS) Scoring|modified Rankin Scale (mRS)",1,15
93,Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease,1,15
94,Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells,1,15
95,ASIA (American Spinal Injury Association) scale|Magnetic Resonance Imaging|MEP/SSEP|ADL (activities of daily living)|SF-36|ODI (Oswestry Disability Questionnaire)|Frequency of Adverse Events,1,15
96,Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.,1,15
97,Fusion|Failure of hardware or obvious non-union|Foot and Ankle Ability Measure (FAAM)|Vitamin D levels|Visual Analog Pain Scale|American Orthopaedic Foot and Ankle Society(AOFAS) hindfoot score|VR-12 (Veterans RAND 12)|Patient-Reported Outcomes Measurement Information System Physical Function-Short Form 8b (PROMIS Item Bank v2.0-Physical Function -Short Form 8b),1,15
98,Security and tolerance|therapeutic effect,1,15
99,Significant MRI Change before and after intervention|Significant neurologic funtion Change before and after intervention|Significant Electrophysiological Change before and after intervention|Adverse event,1,15
100,Magnetic Resonance Imaging|SPECT/CT|Hip X-ray|HHS (Harris Hip Score)|WOMAC (Western Ontario and McMaster Universities) Index|UCLA (University of California Los Angeles) hip questionnaire|Safety evaluation,1,15
101,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)|Number of fractures [ Time Frame: From baseline to 16 months follow-up ]|Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.|Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)|Growth (cm). [ Time Frame: From baseline to16 months follow up]|Weight (kg). [ Time Frame: From baseline to 16 months follow up]|Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]|Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)|Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.",1,15
102,Number of participants with treatment-related adverse events,1,15
103,Serious Adverse Events (SAEs),1,15
104,Visual Analog Scale (VAS)|Western Ontario and McMaster Universities Osteoarthritis Index|Laboratory Asessment|Magnetic Resonance Imaging (MRI) T2 mapping,1,15
105,Improvement in best-corrected distance visual acuity (BCDVA).|Increase in corneal thickness.|Refractive changes|Improvement in anterior corneal surface regularity,1,15
106,Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Efficacy by imaging procedures.|Clinical outcomes.,1,15
107,Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS),1,15
108,Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC),1,15
109,"Adverse events, Safety laboratory values and ECG findings|Immunological reaction|Tumorigenesis",1,15
110,"Number of adverse events|Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment|Overall survival and disease-free survival.|Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.",1,19
111,Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio,1,19
112,Number of treatment related-adverse events during the study period|Improvement in clinical function as assessed by Modified Rankin Score(mRS) compared to baseline at 6 months|Improvement in clinical function as assessed by National Institute of Health Stroke Scale (NIHSS) compared to baseline at 6 months|Improvement in clinical function as assessed by Barthel Index (BI) compared to baseline at 6 months|Improvement in clinical function as assessed by Brain MRI tratogram compared to baseline at 6 months,1,19
113,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 6 Week,1,20
114,Adverse effects after intravenous infusions|Clinical outcome,1,20
115,AE and symptomatic relief|Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler,1,20
116,"Lumbar disc signaling values from magnetic resonance imaging|Visual Analogue Scale (VAS) (0-10 scores, the higher scores mean a worse outcome)|Oswestry Disability Index(ODI) (0-50 scores, the higher scores mean a worse outcome)|The Short Form (36) Health survey (SF36) (0-100 scores, the higher scores mean a better outcome)|Disc Height Index (DHI) from X ray|Size of herniated nucleus pulposus from magnetic resonance imaging|Number of participants with treatment-related adverse events by CTCAE v4.0",1,20
117,Maximum tolerated dose of Descartes-25|Overall Response Rate according to the IMWG response criteria|Median Duration of Response,1,20
118,"Change of bone quality|Number of patients with infection ( increase of local temperature, tenderness, leukocyte count >10,000/ µL, confirmed by Gram stain and blood culture).|Number of patients with bleeding after surgery (Persistent bleeding, ineffectiveness stopping bleeding using dressings)|Number of patients with surgical wound dehiscence (subcutaneous tissue , bone or osteosynthesis material exposed and seen through opened skin )",1,20
119,Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).,1,20
120,Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC),1,20
121,"To Assess the safety of EV-Pure™ and WJ-Pure™ administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.|To assess the efficacy of EV-Pure™ and WJ-Pure™ compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19|Time to clinical improvement|Overall Survival|COVID-19 polymerase chain reaction (PCR) test result as negative",1,20
122,Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR,1,20
123,Number of participants with adverse/serious adverse events,1,20
124,"The mean change in the number of MSCs present in the knee pre- and post- microfracture/microfracture plus arthroscopic synovial brushing.|Number of patients whose clinical effusion scores improve at 3, 6 and 12 months|Number of patients whose semi-quantitative MRI cartilage scores improve at 6 and 12 months|Median KOOS scores at 3, 6 and 12 months (pain; other symptoms; function in daily living; function in sport; knee-related QoL; average score)|Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Visual Analogue Scale (VAS)",1,20
125,Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy,1,20
126,Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC),1,20
127,Changes in ischemic pain|Changes in pain-free walking distance|Changes in TBI (Toe Brachial Index)|Changes in ABI (Ankle Brachial Index)|Change in size of the Ulcer|Determination of maximum tolerable dose according to DLT occurrence|Incidence of abnormal laboratory tests results|Incidence of abnormal blood pressure|Incidence of abnormal temperature|Incidence of abnormal physical condition,1,20
128,Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations,1,20
129,Adverse effects associated with the therapy|Percent of patients with successful pregnancy,1,20
130,Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R),1,20
131,Safety: Number of serious adverse events|DLCO changes from baseline|FVC changes from baseline|exercise capacity changes,1,20
132,toxicity|survival|progression free survival|Rodnan score|Clinical response,1,20
133,Percentage of complications|Change from baseline length and diameter of the stenosis|Crohn's disease activity index (CDAI) questionnaire score|inflammatory bowel disease questionnaire (IBDQ32 )|patients with an obstructive episode who required resection surgery,1,20
134,TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L),1,20
135,adverse effects regarding UCMSC infusion|Pathological score of liver inflammation|Changes of biliary lesions in magnetic resonance image|alanine aminotransferase,1,20
136,Volume Maintenance|Immunophenotyping,1,20
137,FibroScan|IV-C|HA|LN|PC-III|Hepatic histopathologic examination|IgG|IgA|IgM|IgE|C3|C4|CD3|CD4|CD8|CD19|CD16+56|ALB|ALT|AST|TBIL|DBIL|HBV-DNA|Change of ultrasound examination of liver,1,20
138,The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose,1,21
139,fever|Unconsciousness|The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)|FVC,1,19
140,Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms,1,21
141,"Number of Participants With Pre-Specified Infusion Associated Adverse Events|Number of Subjects With Serious Adverse Events by 31 Days After First Infusion|Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity|Subjects With Adverse Events and Serious Adverse Events by Severity|Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment|Subjects With Adverse Events by Relatedness to Treatment|Survival at 31 Days Post First Infusion|Survival at 60 Days Post First Infusion|Time to Recovery|Ventilator-Free Days Throughout 28 Days Post Second Infusion|Ventilator-Free Days Throughout 90 Days|Respiratory Rate and Oxygenation Index (ROX Index)|Oxygenation Index (OI)|Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)|Sequential Organ Failure Assessment (SOFA) Scores|Smell Identification Test (SIT) Scores|White Blood Cell Count (WBC)|Platelets Count|Hemogoblin|Hematocrit|Neutrophils|Lymphocytes|Glomerular Filtration Rate|Total Protein|Sodium|Potassium|Creatinine|Glucose|Albumin|Alkaline Phosphatase|Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)|Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)|Total Bilirubin|Blood Urea Nitrogen (BUN)|Calcium|Chloride|Carbon Dioxide (CO2)|C-Reactive Protein Levels|Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio|D-dimer Levels|25-Hydroxy Vitamin D Levels|Tumor Necrosis Factor-alpha (TNFα)|Tumor Necrosis Factor-beta (TNFβ)|Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)|Viral Load by SARS-CoV-2 RT-PCR|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion|Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG",1,24
142,Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination,1,24
143,To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index|To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test|To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)|To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events,1,24
144,Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses,1,24
145,Number of subjects experiencing adverse events.,1,24
146,"Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372",1,24
147,Death from any cause|Response|Incidence of adverse events|Graft versus host disease status|Proportion of response|Time to complete response|Time to very good partial response|Time to partial response|Incidence of complete response for each organ|Incidence of very good partial response for each organ|Incidence of partial response for each organ|Durability of organ response|Cumulative incidence of non-relapse mortality (NRM)|Cumulative incidence of relapse/progression of the primary disease|Overall survival|Disease-free survival|Graft versus host disease-free survival|Incidence of chronic graft versus host disease|Incidence of systemic infections|Incidence of toxicities|Incidence of any grade cytokine release|Incidence of any infusional toxicity,1,24
148,Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC),1,23
149,"Percentage of wound surface area reduction|Assessment of adverse event (AE) occurrence|Percentage of invisible and visible wound surface area reduction|Absolute wound surface area reduction|Absolute invisible and visible wound surface area reduction|Assessment of wound infection|Time to first complete wound closure|Proportion of patients achieving complete wound closure|Time to first 30% reduction of wound surface area|Proportion of patients achieving 30% reduction of wound surface area|Assessment of wound exudation, epithelialization and formation of granulation tissue|Time to amputation at target leg until Week 12|Pain assessment as per numerical rating scale (NRS)|Assessment of Quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of Dermatology-specific QoL based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs|Time to amputation of target leg until month 12",1,23
150,Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.,1,23
151,Safety and Tolerability assessed by Adverse Events|Number of Antral follicle development|Estradiol (E2) serum level|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Pregnancy rate,1,23
152,Number of Subjects with Dose Limiting Toxicity (DLT) that begins during or following ULSC infusion as assessed within 24 hours.,1,22
153,Time of re-epithelialization|Safety (laboratory tests and adverse events)|Burn Scar Index|healing status of the wound evidenced by photography,1,22
154,MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC|quality of life|RAO Test|intravenous cell transplantation,1,22
155,HbA1c|exogenous insulin requirements|fasting hemoglucose|fasting c-peptide|The incidence and severity of adverse events related to the stem cell infusion procedure,1,22
156,"Safety, recording of Adverse Events and Serious Adverse Events|WOMAC Score|VAS Score|SF-36|The volume of articular cartilage|WORMS Score",1,22
157,Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety,1,21
158,Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale),1,21
159,Arthroscopy|WOMAC total score|WOMAC subscale score|VAS score|RAND-36|IKDC|Biopsy|Use of rescue medication|Kellgren-Lawrence grade,1,21
160,"Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0|Total number of GELs at weeks 4, 12 and 24 after MSC therapy|contrast enhancing lesions identified over months 1, 3 and 6 will be compared between treatment groups.|Comparison of contrast enhancing lesions between treatment periods|Combined unique MRI activity|Relapses|Progression of disability|Disease free patients|MSFC score|peripheral immune responses|Type 4 hypersensitivity reaction",1,21
161,Clinically measured abnormality of laboratory tests and adverse events|Satisfaction as measured by Wexner Score,1,21
162,Clinical response to MSC: Reduction of Crohn's disease Activity score by 100 points or more at six weeks post start of therapy|Incidence of infusional toxicity|Induction of remission|Improved quality of life|Endoscopic improvement.,1,21
163,Number of patients with adverse events (AEs) and serious AEs (SAEs)|Change of liver function evaluated by Child-Pugh Score|Improvement rate of Child-Pugh score|Improvement rate of Child-Pugh grade|Number of patients with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) findings|Number of patients with abnormal pulse rate findings|Number of patients with abnormal body temperature findings|Number of patients with abnormal electrocardiogram (ECG) findings|Number of patients with abnormal clinical chemistry parameters|Number of patients with abnormal clinical hematology parameters|Number of patients with abnormal urinalysis parameters,1,21
164,VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires,1,20
165,Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA),1,20
166,Clinical Examination|MR Elastography|The level of serum alanine aminotransferase (ALT)|The level of glomerular filtration rate (GFR)|The level of serum prothrombin time (PT)|The level of serum total bilirubin (TB)|The level of serum albumin (ALB)|MELD Score,1,20
167,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Pulmonary function test,1,20
168,Severity of adverse events|Magnetic resonance imaging (MRI) of the knee|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),1,20
169,Changes of the Unified Parkinson's Disease Rating Scale (UPDRS)|Changes of in the Hoehn and Yahr staging|Changes of the Mini-Mental State Examination (MMSE)|Changes of the Hamilton depression scales 24 (HAMD 24)|Changes of the Hamilton Anxiety Scale 14 (HAMA-14)|Adverse reaction,1,20
170,Number of participants with treatment-related adverse events|Number of participants with mucosal healing|Number of participants with clinical symptom response|Number of participants with improved healing on pathology,1,20
171,Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation,1,20
172,Adverse events and/or serious adverse events|Change in eGFR Value,1,20
173,"Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 25 days|Change Form Baseline Immune cells: CD3+, CD4+, CD8+, CD16+, CD19+, and CD56+ lymphocytes|Change Form Baseline in pro-inflammatory cytokines: IL-1β, IL- 2, TNF-α, ITN-γ, IL-4, IL-6, IL-10|Change Form Baseline in Immunoglobulins; IgA, IgG, IgM, and IgE.",1,20
174,Adverse effects associated with the therapy|Percent of completely recovered patients with segmental bone tissue defects,1,20
175,Number of patients who didn't require the repeated surgical interventions,1,20
176,Safety (adverse events)|Efficacy: Single Assessment Numeric Evaluation Score (SANE),1,20
177,To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC,1,20
178,Engraftment,1,20
179,AE and ECG parameters|Regional myocardial perfusion and infarct size,1,20
180,Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test,1,20
181,bone gain in periodontal defects(by mm)|the regenerative power of the defect was evaluated by growth factor concentration in GCF.,1,20
182,"Reversal of brain death as noted in clinical examination or EEG|Cerebrospinal fluid (CSF) analysis of color consistency, cell counts, and microbial evaluation|MRI analysis to analyze any changes in meninges|Pulse|O2 saturation|Blood Pressure|Respiration changes",1,20
183,Number of adverse events|Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes|Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)|T-cell function in mixed lymphocyte reaction,1,20
184,Frequency of Adverse Events|Relative Wound Area Regression of 40% or More at 12 Week,1,20
185,To evaluate the safety of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the efficacy of intravenous infusion of MSC in patients with severe to critical COVID-19 pneumonia|To evaluate the effect of MSC administration associated with the standard of care (SOC including anti-viral therapy),1,20
186,Raynaud's Condition Scale|Hand Visual Analogue Scale|Colchin Hand Function Scale|Kapandji Score (Ranging 0 to 10) - Dominant Hand|Kapandji Score (Non-dominant Hand)|Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO)|Disease-related QOL (Quality of Life) : EuroQol Visual Analog Scale (EQ VAS)|Disease-related QOL (Quality of Life) : Health Assessment Questionnaire (HAQ)|The Degree of Hand Edema (Right)|The Degree of Hand Edema (Left)|Changes of Nailfold Capillary Microscopic Findings (Irregularly Enlarged Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Giant Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Hemorrhages)|Changes of Nailfold Capillary Microscopic Findings (Loss of Capillaries)|Changes of Nailfold Capillary Microscopic Findings (Disorganization of the Vascular Array)|Changes of Nailfold Capillary Microscopic Findings (Capillary Ramifications),1,20
187,"Number of participants with Adverse events, complications.|Efficacy",1,19
188,Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test,1,19
189,"clinical and radiological union at 1 month to 6 months|•Safety of Mesenchymal Stem Cells injection in nonunion fractures. Follow-up for revealing any significant immediate or late adverse effects.|Incidence of adverse events in patients (e.g infection , malignancy , ...) Adverse events will be continuously monitored",1,19
190,"Decrease of one grade on the LENT SOMA|The effect of treatment on analgesic drug consumption (analgesic, opiates).|The effect of treatment on quality of life with SF36 questionnaire|The effect of treatment on quality of life with HADS questionnaire|The effect of treatment on pain|Frequency of diarrhea",1,12
191,"Blood serum sample|Free Androgen index (FAI)|Insulin, Glucose Plasma, and Insulin Resistance|Sex Hormone Binding Globulin (SHBG) and Anti-Mullerian Hormone (AMH)|Leptin and Adiponectine Profile|TNFα, IL-1 β, IL-6, IL-10 Profile",1,20
192,Assessment of changes in bone density and quantity|Assessment of bone quantity|Presence of bone formation markers,1,20
193,Knee Society Score|Knee Society Function Score|Magnetic resonance image (MRI) and X-ray assessment|Health related quality of life score (HRQoL) - SF36|Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Visual Analogic Scale (VAS) pain evaluation,1,20
194,Adverse Events of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)|Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD),1,20
195,"Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.",1,20
196,Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC,1,20
197,Health Status using the 36 item Short Form Health Survey (SF-36)|Assessment of Visual Attention and Task Switching|Assessment of Contextual Verbal Learning|Assessment of Verbal Fluency|Assessment of Attention and Executive functions|Assessment of Unstructured Verbal Learning and Memory|Assessment of Visuospatial Learning and Memory|Assessment of Symptoms of Anxiety over Time|Assessment of Pain|Assessment of Sleep Quality|Assessment of Treatment by Participant|Assessment of Depression by Participant,1,20
198,A reduction in the marginal bone levels|Radiographic changes in the marginal bone levels|Reduction in the thickness of the buccal/lingual bone|Changes in the alveolar mucosa|Changes in the width of keratised mucosa,1,20
199,Percentage of complications|Signs improvement|Symptom improvement|Visual acuity improvement|changes in quality of life|evolution of the conjunctival flora,1,20
200,Ventilator Free Days,1,20
201,Left ventricular ejection fraction|Left ventricular end diastolic volume|Left ventricular end systolic volume|Stroke volume|Left ventricular apex four-chamber end systolic diameter|6 minutes walking distance|THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF,1,20
202,Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate,1,20
203,Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS),1,20
204,Major Adverse Events Analysis (MAEs)|Ankle-Brachial Index (ABI)|Digital subtraction angiography (DSA)|Thermography|Wong-Baker FACES Pain Rating Score|Treadmill test,1,20
205,Validity evaluation by detection of the Model for end-stage Liver Disease score of participants|Safety evaluation by detecting Blood routine|Validity evaluation by detection of the child-pugh of participants,1,20
206,Number of participants with adverse events|Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS)|Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale|Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT)|Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test|Number of participants with a change in mobility and leg function as measured by the 25 foot walking test|Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire|Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG)|Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI),1,20
207,Number of Adverse events and serious adverse events (AEs or SAEs)|Change of liver function through the Model for End Stage Liver Disease (MELD) score|Change in health-related quality of life using Chronic Liver Disease Questionnaire - (CLDQ),1,20
208,The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells,1,20
209,Gene Measurements|Wound Size|Infection|Pain Level,1,20
210,Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS),1,20
211,Change from Baseline Pain at 15th day|Change from baseline maximum mouth opening at 15th day|Change from baseline maximum mouth opening at 1 month|Change from baseline maximum mouth opening at 3 months|Change from baseline maximum mouth opening at 6 months|Change from baseline pain at 1 month|Change from baseline pain at 3 month|Change from baseline pain at 6 month|Change from baseline 'comfort ' at 6th month,1,20
212,"The number of (S)AESI [(Serious) Adverse Event of Special Interest]|Disease progression|Pulmonary function decline|Muscle strength decline|Upper motor neuron function|Cognitive function|Quality of life changes|The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)|The change of defined cytokines, chemokines level in blood|The change of creatinine and p75ECD level in urine|Muscle function changes|The change of the brain visualization|SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI|Survival period to disease progression|Mortality rate",1,20
213,Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction,1,20
214,"Overall Survival (OS)|Liver function improvement|The size of liver and the width of portal venous|Incidence of hepatocellular carcinoma within 1 year|Child-Pugh score, MELD score,SF36-quality of life (SF36-QOL)|The clinical symptom improvement(including appetite, debilitation, abdominal distension, edema of lower limbs, et al )",1,20
215,SCI evaluation and patients follow up|SCI evaluation and MSCs transplantation,1,20
216,Safety assessed by dose limiting toxicity (DLT)|Safety assessed by dose limiting toxicity|Safety assessed by change in spirometry|Safety assessed by all adverse events|Change in patient reported outcomes|DAS28-CRP,1,20
217,Healing rate|Incontinence rate|Treatment related adverse events,1,12
218,"Assessment of quality of life (QOL) via 36-Item Short Form Survey (SF-36) change from baseline at 6 and 12 months.|Assessment of disabilities of arm, shoulder, hand via DASH Questionnaire change from baseline at 6 and 12 months.|Assessment of erectile function via International Index of Erectile Function (IIEF-5) change from baseline at 6 and 12 months.|Assessment of COPD via Clinical Chronic Obstructive Pulmonary Disease Questionnaire change from baseline at 6 and 12 months.|Assessment of mental state via Mini Mental State Examination (MMSE) change from baseline at 6 and 12 months.|Assessment of interstitial cystitis via O'Leary/Sant Questionnaire change from baseline at 6 and 12 months.|Assessment of back pain via Oswestry Low Back Pain Disability Questionnaire change from baseline at 6 and 12 months.|Assessment of osteoarthritis via Western Ontario and McMaster Osteoarthritis Index (WOMAC) change from baseline at 6 and 12 months.",1,5000
219,Safety of hCT-MSC infusion as measured by incidence of infusion reactions|Safety of hCT-MSC infusion as measured by severity of infusion reactions|Safety of hCT-MSC infusion as measured by incidence of product-related infections|Safety of hCT-MSC infusion as measured by severity of product-related infections|Safety of hCT-MSC infusion as measured by evidence of alloimmunization via anit-HLA antibodies|Safety of hCT-MSC infusion as measured by incidence of graft vs. host disease|Safety of hCT-MSC infusion as measured by severity of graft vs. host disease|Safety of hCT-MSC infusion as measured by incidence of unexpected adverse events|Safety of hCT-MSC infusion as measured by severity of unexpected adverse events|Change in PDD Behavior Inventory Autism Composite Score (PDDBI)|Change in mean of the Socialization Subscale and Communication Subscale standard scores on the Vineland Adaptive Behavior Scales (VABS-3)|Change in Clinical Global Impression Scale (CGI)|Change in Communicative Development Inventories (CDI-2)|Change in attention abilities as assess via eye-tracking|Change in brain activity as measured by EEG,1,12
220,Number of subjects with adverse drug reactions|Respiratory outcomes|Survival|Z-score|Potential neurological development test outcomes,1,8
221,Number of Participants Who Demonstrated Acute Adverse Events Following Infusion|Percentage Change in Lung Function as Assessed by FVC Compared to Baseline|Percentage Change in 6 Minute Walk Distance Compared to Baseline|Percentage Change in Lung Function as Assessed by DLCO Compared to Baseline,1,8
222,Incidence of adverse events|Incidence of abnormal results of Physical examination|Percentage of abnormal Vital signs|Percentage of abnormal results of Laboratory tests|SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)|BILAG 2004 (British Isles Lupus Assessment Group 2004)|SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index|Disease activity assessed by PGA (Physician Global Assessment),1,7
223,Safety evaluation|Alterations in SARA score|Positron emission tomography|Magnetic resonance spectroscopy|Assessment of language and swallowing functions|Evaluation of syncope|Balance test,1,7
224,Safety assessment(evaluation),1,7
225,The number of donors needed to obtain 3 BM harvest.,1,7
226,Incidence of any treatment-emergent adverse events (TE-AEs)|Clinical healing,1,7
227,To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.|To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.,1,7
228,The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test,1,7
229,Pain at injection site: grade|Infection at injection site|Bleeding at injection site|Eyelid function disorder|Periorbital edema|Ocular discomfort|Flu-like symptoms|Fever|OSDI questionnaire|Schirmer's I test|Tear osmolarity|Ocular SICCA Grading Score|HLA anti-bodies,1,7
230,Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks,1,7
231,Wound Healing|Wound Pain|Measured Quality of Life|Systemic Infection|Survival State,1,7
232,mass formation|Creatinin|GFR,1,7
233,Incidence of adverse events (AEs) related to intervention|Incidence of serious adverse events (SAEs) related to intervention|Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）,1,7
234,Efficacy evaluation|Safety eveluation,1,7
235,Incidence of adverse events of intravenous injection of human mesenchymal stem cells (hMSCs) in patients with recent onset left ventricular systolic dysfunction from anthracyclines|Change in improvement in left ventricular systolic function by 7 points|Development of acute heart failure decompensation|Emergency center visits for heart failure|Need for new pacemaker/automatic implantable cardioverter defibrillator|New onset arrhythmias|Sudden cardiac death|Acute pulmonary edema|Asymptomatic decrease in left ventricular ejection fraction (LVEF) of > 10%|Heart failure admission|Progression free survival,1,7
236,Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.,1,6
237,Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery,1,6
238,Proportion of Participants who Achieve Operational Tolerance|Proportion of Participants who Remain Off Immunosuppression|Proportion of Participants who Return to Immunosuppression|Proportion of Participants who Achieve Belatacept Monotherapy|Proportion of Participants who Die|Time from Transplant to the First Episode of Rejection|Incidence of Participants who Develop Donor Specific Antibody (DSA)|Incidence of Adverse Events Attributable to Mesenchymal Stromal Cells (MSC) Administration|Frequency of Select Adverse Events (AEs)|Incidence of Post-Transplant Diabetes|Frequency of Antibody-Mediated Acute Cellular Rejection|Frequency of Antibody-Mediated Chronic Rejection,1,6
239,"Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms|Preliminary efficacy of Cellavita HD by UHDRS improvement and global clinical response (CIBIS)|Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers|Immunological Response of Cellavita HD|Preliminary efficacy of Cellavita HD by comparison of the CNS assessment|Risk of suicidal ideation by Hamilton Depression Rating Scale (HDRS)",1,6
240,Knee cartilage defects|pain,1,6
241,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes in exercise performance using 6-min walk test (6MWT).|Changes in grip strength.|Changes in quality of life measured by change in SF12 (12-Item Short Form).|Changes in physical activity using International Physical Activity Questionnaire (IPAQ) questionnaire|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in Clinical Frailty Scale.,1,6
242,Renal blood flow and function in the treated kidneys.|Level of kidney function.,1,6
243,safety|pain|physical function|defect,1,6
244,To evaluate the safety of the stromal cell infusion,1,8
245,success rate of fibroblasts culture|success rate of turning fibroblasts into mesenchymal stem cells|success rate of CRISPR/Case9 gene therapy treatment on patients' cells,1,8
246,swelling of hip joint|deterioration of joint function|skin allergic reaction|Respiratory reaction|Quantitative changes in pain intensity|physical function improvement|subchondral bone edema|cartilage thickness,1,6
247,PASI score improvement rate|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI(Dermatology Life Quality Index),1,8
248,Change from baseline in safety|Change from baseline in effectiveness by MRI|Feasibility|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect,1,9
249,"Dose-Limiting Toxicity and Maximum Tolerated Dose of CS10BR05 Inj.|Adverse events, frequency and rate of vitals sign, laboratory test, physical examination, ECG, etc.|Unified Multiple System Atrophy Rating Scale(UMSARS)",1,9
250,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaire,1,9
251,"Incidence of adverse events|Clinical remission (proteinuria, hematuria)|Proteinuria|Hematuria|Estimated glomerular filtration rate (eGFR)",1,9
252,Oxygen saturation|Oxygen pressure in inspiration|ground-glass opacity|Pneumonia infiltration|Lactate dehydrogenase|C-reactive protein|D-dimer|Ferritine,1,9
253,"Incidence of Adverse Events Incidence of Adverse Events|Change in Model for End-Stage Liver Disease (MELD) score from baseline to 28th day|Change in Model for End-Stage Liver Disease (MELD) score from baseline to 3 days, 7days, 14 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, and 24 months|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|plasma prealbumin (PALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin time (PT)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|Incidence of liver cancer|ChronicLiver Disease Questionnaire (CLDQ)",1,9
254,Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.|Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires,1,9
255,Safety (Clinically measured abnormality of laboratory tests and adverse events)|CDAI value|The ratio of patients applicable to CDAI <150,1,9
256,"Incidence of adverse events|Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)|Mortality|Overall survival|Duration of continuous respiratory support|Duration of continuous use of vasopressors or pulmonary vasodilators|The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition|The developmental quotient in Kyoto Scale of Psychological Development 2001|Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words|Presence of spasticity|Presence of epilepsy|MRI score|Gross Motor Function Classification System (GMFCS) score",1,9
257,Number and frequency of adverse events (AEs)|Changes of vital signs from 1 hour after infusion to day 28±3|Changes of complete blood count (CBC) from day 1 to day 28±3|Changes of blood biochemical from day 1 to day 28±3|Changes of coagulation function from day 1 to day 28±3|Routine urine analysis|Urine pregnancy test (female only)|Cardiac rate measured by twelve-lead electrocardiogram|Percentage of participants achieving ACR20|Percentage of participants achieving ACR50|Percentage of participants achieving ACR70|Change from baseline of the disease activity score based on DAS28-CRP|Change from baseline of the disease activity score based on DAS28-ESR|EULAR response|Change from baseline of the health assessment questionnaire(HAQ) score|Change from baseline of the simplified disease activity index (SDAI) score|Change from baseline of the clinical disease activity index (CDAI) score|Change from baseline of TNF-α level|Change from baseline of IL-6 level,1,9
258,Occurrence of adverse events|Changes in neurological function test,1,9
259,Safety and tolerability of BC-101 injection|Changes in wrinkle severity assessment from baseline,1,9
260,Change from the baseline in ADAS-Cog|Change in CDR-SOB|Change from the baseline in K-MMSE(korean version)|Change from the baseline in CGA-NPI|Change from the baseline in SIB|ADAS-Cog Response Rate|Change in CIBIC-plus|Change from the baseline in CSF biomarkers,1,9
261,Grading of Adverse Events|Routine physical examinations|Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]|Changes in vital signs: blood pressure [Safety of Mitocell]|Changes in vital signs: pulse rate [Safety of Mitocell]|Changes in vital signs: body temperature [Safety of Mitocell]|Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]|Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]|Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]|Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]|Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]|Electrocardiogram (ECG)|Magnetic Resonance Imaging (MRI)|MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)|Modified Hoehn & Yahr staging|18F-DOPA PET|levodopa equivalent daily dose (LEDD)|PDQ-39 (Parkinson's Disease Questionnaire)|Beck Depression Inventory (BDI-II) scores|Hamilton Depression Rating Scale (HAM-D-17) scores|Mini Mental State Examination (MMSE) Scores,1,9
262,Number of adverse events|Sensory and motor strength|Functional Independence|Muscle strength assessment,1,9
263,Number of participants with Adverse event|Changes from the baseline in ADAS-cog at 12 weeks post-dose,1,9
264,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Modified Rankin Score (mRS)|Changes in National Institute of Health Stroke Scale (NIHSS)|Changes in Barthel Index (BI)|Changes in Brain MRI,1,9
265,"The incidence and frequency of adverse events related to administration of UMC119-01.|The percentage of subjects who died from any cause during the study.|Changes of the oxygen saturation.|Changes of chest x-ray findings in participants before and after administration.|Changes of inflammatory markers (pg/ml) before and after administration.|Comparison of the incidence and severity of preterm children's complications in participants before and after administration.|The number of days of intubation, or where ventilator or oxygen therapy.|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).",1,9
266,Safety assessment(evaluation)|Efficacy assessment(evaluation),1,8
267,Fever|Unconscious|Vomiting|ALS-FRS|FVC,1,8
268,safety evaluation,1,8
269,Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence,1,8
270,Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）,1,8
271,Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments,1,6
272,Incidence of treatment-emergent adverse events (AE)|Blood anti-Müllerian hormone (AMH) level|Day 3 follicle stimulating hormone (FSH) and estradiol (E2) levels|Antral follicle counts (AFC),1,6
273,Safety events|Maximum tolerated dose (MTD),1,12
274,Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.,1,5
275,Maximum Tolerated Dose (MTD) of Mesenchymal Stem Cells-Interferon-β (MSC-IFNβ)|Correlation Between the Number of MSC-IFNβ Infused and the Production of Interferon-β and the Number of MSC-IFNβ Detected at the Tumor Sites Via Tumor Biopsy Pre- and Post-Treatment,1,5
276,Magnetic resonance imaging|Sensitivity and motor strength on the inferior limbs|Improvement in urological function|Improvements in sensorial mapping and neuropathic pain,1,5
277,"To determine the safety or repeated infusions of donor-derived and MSCs in subjects with severe osteogenesis imperfecta > 5years after an allogeneic bone marrow transplant and no prior bone marrow transplant.|To determine if MSCs elicit an immune response after repeated infusions.|To determine the change in clinical course (growth, bone mineral content, fracture rate, development/activities) of subjects after experimental MSC intervention therapy as compared with each subject's own pre-MSC intervention therapy.",1,5
278,To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.|Change in MELD (Model for End stage Liver disease) score.|Change in Child Pugh score.|Change in the percentage of CD 34 cells in liver.,1,5
279,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire|Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.,1,4
280,Major adverse cardiac events (MACE) endpoints of mortality|Re-infarction|Target vessel revascularization (TVR)|Heart failure hospitalization|Cardiac MRI|Echocardiography|Electrocardiography (ECG)|Wellness Parameter|Laboratory Assessment,1,4
281,1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection|Confirmation of the degree of pain improvement in VAS|Confirmation of the degree of improvement in disability (ODI)|Confirmation of increase in water content in the nucleus using MRI,1,4
282,"C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes",1,3
283,Measurment of Cell Viability and Apoptosis|Measurment of cell differantiation,1,3
284,ALT|AST|Serum Albumin|Liver Fibrosis|Progression of fibrosis,1,3
285,Osteogenic Effects in Human Mesenchymal Stem Cells Enhanced by Wnt Signaling/Hydroxyapatite Nanoparticles--Comparisons between Non-viral and Viral administration in Tissue Engineered Bone Regeneration,1,3
286,Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R),1,3
287,Incidence of Treatment-Emergent Adverse Events (TEAEs)|Incidence of Treatment-Emergent Adverse Events|Changes of pain after stem cell injection|Changes of PUF (Pelvic Pain and Urgency/Frequency) scores after stem cell injection|Changes of ICQ (O'Leary-Sant interstitial cystitis symptom index/problem index) scores after stem cell injection|Changes of voiding profiles after stem cell injection|Changes of Hunner lesion after stem cell injection,1,3
288,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure,1,2
289,Adverse Events as a Measure of Safety|bone mineral density|fracture rate|growth velocity|change from baseline in degree of functionality|change from baseline in well-being,1,2
290,Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR)|Changes in Visual Acuity|Changes in Visual Field|Changes in Optical Coherence Tomography Parameters Related to Glaucoma|Changes in Retinal Ganglion Cells Function by ERG,1,2
291,Safety|Neurologic disability score,1,1
292,"Change in acute phase reactants (C-reactive protein (CRP) after MSC administration in group I, II, III|Change in acute phase reactants (procalcitonin) after MSC administration in group I, II, III|Change in acute phase reactants ( white blood cell count) after MSC administration in group I, II, III|Changes in respiratory support after MSC administration in Groups I, II, III|Changes in arterial blood gas analysis (partial oxygen/fractionated oxygen (Pa/Fi) ratio) after MSC administration in Groups I, II, III|Effect on mortality after MSC administration in Groups I, II, III",1,1
293,Safety evaluation|Positron emission tomography|Magnetic Resonance Imaging|Electroencephalogram|Neuropsychological assessment|Electrodiagnostic Testing|Assessment of language and swallowing functions|Measure of the severity of disability|Assessment of spasticity and strength|Assessment of brain motor control,1,1
294,Sperm detection|Hormonal profile,1,1
295,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment.",1,1
296,Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %,1,1
297,Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan,1,1
298,MSC identification using MRI in-vivo on day 0|MSC identification using MRI in-vivo on day 1|MSC identification using MRI in-vivo on day 7|MSC identification using MRI in-vivo after 2 weeks|MSC identification using MRI in-vivo after 4 weeks|MSC identification using MRI in-vivo after 8 weeks|MSC identification using MRI in-vivo after 12 weeks|MSC identification using MRI in-vivo after 26 weeks|Cardiac pump function changes|CCS class|Seattle Angina Questionnaire|Weekly number of angina attacks|Weekly nitroglycerin consumption|Adverse events,1,5
299,"Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months",1,5
300,Safety: Adverse Event,1,6
301,PASI score improvement rate|Psoriasis Area and Severity Index(PASI)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|the Body Surface Area (BSA%)|the Dermatology Life Quality Index（DLQI）,1,5
302,Number of participants with Adverse event|Amount of change in late gadolinium contrast-enhanced area at the time of screening and 6 months after surgery|Number of complication associated with drug administration method,1,6
303,The incidence and frequency of adverse events related to administration of UMC119-06-05.|Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.|Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).|Whole Organ Magnetic Resonance Imaging Score (WORMS).|Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.|Amount of rescue medications required.,1,6
304,Number of participants with treatment-related adverse events|Bone regeneration as assessed by high-resolution CT scans|Quality of life as measured by the Glasgow Benefit Inventory|Quality of life as measured by SF-12,1,6
305,Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT)|Overall Survival 6 Months Following HCT|Overall Survival 1 Year Following HCT|Count of Participants With Disease-free Survival 6 Months Following HCT|Count of Participants With Disease-free Survival 1 Year Following HCT,1,6
306,Mass formation|Glomerular Filtration Rate (GFR),1,6
307,Fever|Unconsciousness|vomiting|ALS-FRS|FVC|EMG-NCV,1,6
308,Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft versus host disease incidence in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft failure incidence in haploidentical stem cell transplantation,1,6
309,Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause,1,6
310,Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume,1,6
311,fulfill bone cyst defect|effect of mesenchymal cell transplantation,1,6
312,Incidence of Treatment-Emergent Adverse Events|Proportion of complete wound closure,1,6
313,Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum,1,6
314,Pain relief,1,6
315,Radiological progression of bone fusion|Reduction of pain using VAS|Cost analysis based on length of hospital stay,1,6
316,effect of mesenchymal cell transplantation to decrease limb inequal|improve life quality,1,6
317,Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal,1,5
318,Amount of New Bone Mass Formed|Quality of Bone Regeneration,1,5
319,Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell|Change in type VII collagen and anchoring fibril expression at dermoepidermal junction|Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)|Change in Global severity score|Change in total body surface area affected by RDEB|Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire|Change in blister count|Change in pruritus visual analogue scale (VAS)|Change in pain visual analogue scale (VAS),1,5
320,Incidence of adverse reactions|Incidence of opportunist diseases|Changes in CD4+ cell count and CD4+/CD8+ ratio|T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks,1,5
321,Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale,1,5
322,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Time to reach re-epithelialization of wound|Vancouver Burn Scar Scale,1,5
323,Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale|Adverse events procedure-related (intravitreal injection),1,5
324,The volume change of fatty layer|Clinical lab tests|Fat absorption rate,1,5
325,Incidence of grade 3-5 infusional toxicities and predefined hemodynamic or respiratory adverse events related to the infusion of MSC|Incidence of a reduction in one or more biomarkers of inflammation by day 7|Trend changes in PaO2:FiO2 ratio|Trend changes in Mean Airway Pressure|Trend changes in peak pressure|Trend changes in plateau pressure|Trend changes in Positive end-expiratory airway pressure (PEEP)|Incidence of mortality|Number of ICU-free days|Number of days alive and ventilator free composite score 3|Change in acute lung injury (ALI) score 2|Incidence of serious adverse events|Number of days alive off supplemental oxygen,1,9
326,Number of product related adverse events through the duration of the study.|Secondary Endpoint,1,9
327,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.|Level of cytopenias|Transfusional requirements|Incidence of infections and febrile neutropenia,1,9
328,Tumor formation|Adverse events,1,11
329,To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts|Indication of efficacy,1,11
330,iMP-related adverse events|Hypersensitivity|Scar reduction|LVEF|Change in quality of life,1,11
331,Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival,1,11
332,Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray,1,11
333,Response by Day 28|Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at day 1|Best stage of each involved organ by Day 28|Time to improvement or resolution of GVHD in one or more organs|Adverse events|Infusional toxicity|Overall relapse of underlying disease|Overall survival|Formation of ectopic tissue foci|Incidence of infection,1,11
334,differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies,1,10
335,proportion of participants who have a TRSAE after infusion of MSCTC 0010|Proportion of participants who achieve a complete response (CR) of aGVHD by study day 42|Proportion of participants with improvement of GVHD in 1 or more organs involved with GVHD by day 42|Occurrence of addition of escalated immunosuppressive therapy by day 90|Occurrence of Formation of ectopic tissue foci at day 90,1,10
336,Safety of inject mesenchymal stem cells in MMII|Quality of life of patients after treatment,1,10
337,change in bone volume,1,10
338,"biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses",1,10
339,Treatment related adverse events|Complete clinical healing|Partial clinical healing|Lack of response|Worsening of disease,1,10
340,Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system|Incidence of Serious adverse event (SAE) as presented by MedDRA coding system|Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system|New York Heart Association (NYHA) Classification|Incidence of major adverse cardiovascular events (MACE)|Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)|Pulmonary function test|Echocardiogram|Cardiac MRI (cMRI) for baseline and efficacy evaluation,1,10
341,"Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)|Changes in eGFR|Changes in BUN|Changes in Creatinine",1,10
342,Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points|Number of Participants with Reduction in CDAI of at Least 70 points|Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)|Time to Improvement in IBDQ|Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression|Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150|Time to Reduction in CDAI of at Least 100 Points|Time to Reduction in CDAI of at Least 70 Points|Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.|Number of Participants with Adverse Events,1,10
343,"Treatment related adverse events|Number of subjects with treatment related abnormal variation of vital signs, physical examination and laboratory test values|Oxygenation index (PaO2 / FiO2 ratio)|Mortality rate|Ventilator treatment status|Improvement of pneumonia|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test",1,10
344,Cartilage Repair|Visual Analog Score for pain|International Knee Documentation Committee Questionnaire|Western Ontario and McMaster Universities Osteoarthritis Index|Perioperative and post-operative complications|Measurement of health resources expenses,1,10
345,SDF1-α (stromal cell-derived factor alpha) Concentration|DPP-4 (Dipeptidyl peptidase-4) Activity|Monocyte State|Absolute/Differential leukocyte count|CD271+ cells,1,10
346,Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]|Acute GVHD-restaging [Efficacy]|Chronic GVHD-restaging [Efficacy]|Survival analysis at six months after MSC infusion|Incidence free survival at six months after MSC infusion,1,10
347,Safety measure|HbA1c|Fasting blood glucose (FPG)|C-peptide levels|Blood insulin|Insulin dose,1,10
348,"Feasibility and security of MSC therapy in very low birth weight preterm babies at risk of developing bronchopulmonary dysplasia (Number of participants with adverse events)|Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.|Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)|Incidence of BPD and PH in very low birth weight babies treated with MSC",1,10
349,Osteogenic potential|Adipogenic potential|Genotype assay,1,10
350,Assessment of changes in the bone volume at the grafted alveolar cleft site from the immediate postoperative to 6 months|Assessment of changes in the bone density at the grafted alveolar cleft site from the immediate postoperative to 6 months,1,10
351,- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate|- AGVHD grade,1,10
352,Union|Short Form 12 survey,1,11
353,The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life,1,11
354,Number of participant with adverse reaction|Incidence of BPD at 36 Week's postmenstrual age,1,9
355,IKDC Score|VAS|Lysholm Score|KOOS Score,1,12
356,Treatment related adverse events|Clinical and endoscopic remission|Clinical and endoscopic response|Partial clinical and endoscopic response|Lack of response|Mayo clinic score,1,24
357,"The number of Serious Adverse Events that are attributable to the treatment|The severity of Serious Adverse Events that are attributable to the treatment|Amputation free survival|median time to amputation,|Change in Transcutaneous Pressure of Oxygen TcPO2|Change in Ankle Brachial Index|Collateral vessel formation|Change in Ischemic rest pain|Change in Ulcer size|Change in Quality of Life",1,12
358,"Change of total score in WOMAC (Western Ontario and McMaster University)|Change of score in WOMAC three subscales (Pain, stiffness, physical function)|Change of score in 100 mm VAS (Visual Analogue Scale)|Change of score in IKDC(International Knee Documentation Committee)|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score)|Change in K&L(Kellgren-Lawrence) grade|Change in joint space width|Change in mechanical axis, anatomical axis|Rate of surgery to treat application site after treatment of SMUP-IA-01|Changes in biomarker",1,12
359,"Incidence of infusion reactions|Incidence of product-related infections|Evidence of formation of anti-HLA antibodies|Incidence of graft vs. host disease|Incidence of unexpected adverse events, by severity and relation to study|The Vineland Adaptive Behavior Scale Interview, 3rd Edition, Comprehensive interview form|Social Responsiveness Scale, Second Edition (SRS-2)|Social Withdrawal Subscale of the Aberrant Behavior Checklist, Community Edition (ABC-C)|Pediatric Quality of Life Inventory General Core Scales|Pediatric Quality of Life Inventory Family Impact Measure|Pediatric Quality of Life Inventory General Core Scales - Adult Version",1,12
360,Percent of participants with response to therapy|aGVHD severity per Blood and Marrow Transplant Clinical Trials Network Manual of Operations (BMT MOP).|aGVHD incidence|Safety as measured by number of adverse events attributed to MSC and ECP therapy|Safety as measured by severity of adverse events attributed to MSC and ECP therapy|Number of participants with non-relapse mortality (NRM)|Number of participants with relapse-related mortality|Average time to relapse|Chronic GVHD incidence|Overall Survival (OS)|Steroid dose decrease|Steroid discontinuation rate|Change in FACT-BMT (Functional Assesment of Cancer Therapy-Bone Marrow Transplant) survey score|Percent regulatory T cells (% Tregs)|CD4:CD8 ratio,1,12
361,Incidence of Infusion reactions|Incidence of Infections,1,12
362,Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size|Change in salivary gland stiffness measured by shear wave velocity|Participant Drop out Rate,1,12
363,Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.|Death rate or rehospitalization due to cardiovascular causes|Rate of relevant arrhythmias in Holter of 24 hours|Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels|Changes in the necrotic myocardial mass ratio|Changes of regional contractility|Changes in ejection fraction of the left ventricle|changes in left and right ventricular geometric remodeling|Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).|Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used.,1,12
364,Change From Baseline in Visual Analog Scale (VAS) at 6 and 12 Weeks|Modified Mayo Clinic Performance Index for the Elbow|Defect Area of Tendon by Ultrasonography in Long Axis|Defect Area of Tendon by Ultrasonography in Short Axis,1,12
365,Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI),1,12
366,Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee.|Indication of Efficacy,1,12
367,Changes in IIEF-5 Score after stem cells injection|Changes in Peak Systolic Velocity (PSV) after stem cells injection|Changes in End Diastolic Velocity after stem cells injection|Changes in Resistive Index after stem cells injection|Changes in Pulsatility Index after stem cells injection|Changes in E-selectin expression after stem cells injection|Changes in Vascular Endothelial Growth Factor (VEGF) expression after stem cells injection|Changes in Bcl-2 expression after stem cells injection|Changes in microRNA 16 expression after stem cells injection|Changes in microRNA 126 expression after stem cells injection|Changes in Hba1c after stem cells injection|Changes in Fasting Blood Glucose after stem cells injection|Changes in total cholesterol after stem cells injection|Changes in low-density lipoprotein (LDL) after stem cells injection|Changes in high-density lipoprotein (HDL) after stem cells injection|Changes in Triglycerides (TG) level after stem cells injection|Number of participants with side effects after intracavernosal injection,1,12
368,Number of patients who didn't require the repeated surgical interventions|Tracheostomy decannulation,1,12
369,"Change of total score in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) compared to baseline at 6 months after treatment|Change of score in WOMAC three subscales (Pain, stiffness, physical function)compared to baseline at 6 months after treatment|Change of score in 100 mm VAS (Visual Analogue Scale) compared to baseline|Change of score in IKDC(International Knee Documentation Committee)compared to baseline|Change of score in WORMS(Whole-Organ Magnetic Resonance iMaging Score) compared to baseline at 6 months after treatment|Change in K&L(Kellgren-Lawrence) grade compared to the baseline at 3 months and 6 months after treatment|Change in joint space width compared to the baseline at 3 months and 6 months after treatment|Change in mechanical axis, anatomical axis compared to the baseline at 3 months and 6 months after treatment",1,12
370,Safety and tolerability after hAMSCs injection.|The ratio of transplantable embryo in DOR patients after hAMSCs injection.|Ovarian function in DOR patients after hAMSCs injection.|Outcomes of IVF in DOR patients after hAMSCs injection.,1,12
371,Worsening kidney allograft rejection|Adverse Events,1,12
372,Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks|Change in participant QoL: XeQOL|Change in participant QoL: MDADI|Change in participant QoL: VAS|Change in participant Salivary Function: Unstimulated|Change in participant Salivary Function: Stimulated|Change in participant Salivary Gland Size,1,12
373,Child Pugh Score|Examination of liver function|MELD Score,1,12
374,"Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with 12-lead Electrocardiography (ECG) abnormalities|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Change from baseline in disease severity CMTNS-v2 score|Change from baseline in gait and balance functions|Change from baseline in the degree of muscle damage (%)|Change from baseline in nerve regeneration potential",1,12
375,"Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence|Immunological reaction",1,12
376,To determine DLT (Dose limiting toxicity)|adverse events as assessed by CTCAE v5.0|ADAS-Cog 13 response rate|The Clinical Dementia Rating Sum of Boxes|Alzheimer's Disease Cooperative Study- instrumental items of the Activities of Daily Living Inventory|Caregiver-administered Neuropsychiatric Inventory|preliminary efficacy|K-MMSE,1,12
377,"Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with abnormalities of 12-lead Electrocardiography (ECG)|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Rate of change at the time of visit compared to baseline (percent [%]) in CK level|Change from baseline in Function tests",1,12
378,Change in number of adverse events and severe adverse events post-intervention|Number of grade ≥3 adverse reaction attributable to the γMSC product|Change in lung function test|In- vivo trafficking of MSCs after intravenous infusion|Upper airway inflammation of MSC treatment|Circulating inflammatory cells of MSC treatment|Biophysical characteristics of the cell products and correlation with clinical outcome,1,12
379,"Measurement of b-FGF, v-EGF MEASURED BY ELISA|Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.|Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study|Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.|Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion|Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %",1,10
380,Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide,1,10
381,"Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.",1,10
382,Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire,1,10
383,Number of Participants with Adverse Events as a Measure of Safety and Tolerability,1,10
384,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of WJMSC,1,10
385,"Safety Evaluation assessed by Tumor Marker Test.|Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer.|Safety Evaluation assessed by Vital Signs.",1,10
386,"Composite indicators, including quantitative analysis of CT density histograms, self-evaluation and changes of TGF-β1 content|Safety Evaluation|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in pulmonary function analysis|Clinical Indicator 3: 6-minute walk test distance|Clinical Indicator 4: change in MRC chronic dyspnea scale|Clinical Indicator 5: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum 1: T lymphocyte counts in peripheral blood|Immunological Indicator in serum 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in serum 3: concent of immunoglobulin|Immunological Indicator in serum 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in serum 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in serum 6: expression levels of IL-12, IL-10|Immunological Indicator in lavage fluid 1: T lymphocyte counts in peripheral blood|Immunological Indicator in lavage fluid 2: response level of CD4+ T lymphocyte subsets (such as Th1 / Th2)|Immunological Indicator in lavage fluid 3: concent of immunoglobulin|Immunological Indicator in lavage fluid 4: expression levels of various cytokines (IL-1, IL-3, IL-6, IL-8, TNF-α, GM-CSF, etc)|Immunological Indicator in lavage fluid 5: subtype analysis and phagocytic activity analysis of macrophage|Immunological Indicator in lavage fluid 6: expression levels of IL-12, IL-10|Inflammatory Indicators: measured by routine blood test including C-reactive protein (CRP)|Fibrosis Indicators in serum 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in serum 2: content of hydroxyproline|Fibrosis Indicators in serum 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)|Fibrosis Indicators in lavage fluid 1: content of transforming growth factor -α/β (TGF-α/TGF-β)|Fibrosis Indicators in lavage fluid 2: content of hydroxyproline|Fibrosis Indicators in lavage fluid 3: content of matrix metalloproteinase 1/7(MMP1/MMP7)",1,10
387,Treatment-emergent adverse events (TEAEs)|Change from baseline in the systolic blood pressure after 20 days of treatment|Change from baseline in the diastolic blood pressure after 20 days of treatment|Change from baseline in the heart rate after 20 days of treatment|Change from baseline in the respiratory rate after 20 days of treatment|Change from baseline in the body temperature after 20 days of treatment|Change from baseline in the basophils after 20 days of treatment|Change from baseline in the eosinophils after 20 days of treatment|Change from baseline in the hemoglobin after 20 days of treatment|Change from baseline in the lymphocytes after 20 days of treatment|Change from baseline in the monocytes after 20 days of treatment|Change from baseline in the red blood cell after 20 days of treatment|Change from baseline in the white blood cell after 20 days of treatment|Change from baseline in the bicarbonate after 20 days of treatment|Change from baseline in the blood urea nitrogen after 20 days of treatment|Change from baseline in the calcium after 20 days of treatment|Change from baseline in the chloride after 20 days of treatment|Change from baseline in the creatinine after 20 days of treatment|Change from baseline in the glucose after 20 days of treatment|Change from baseline in the potassium after 20 days of treatment|Change from baseline in the sodium after 20 days of treatment|Change from baseline in the alanine transaminase after 20 days of treatment|Change from baseline in the albumin after 20 days of treatment|Change from baseline in the alkaline phosphatase after 20 days of treatment|Change from baseline in the aspartate aminotransferase after 20 days of treatment|Change from baseline in the direct bilirubin after 20 days of treatment|Change from baseline in the total bilirubin after 20 days of treatment|Change from baseline in the c-reactive protein after 20 days of treatment|Change from baseline in the erythrocyte sedimentation rate after 20 days of treatment|Assessment of the dryness of the area of application|Assessment of the oozing/crusting of the area of application|Assessment of the redness of the area of application|Assessment of the scratch marks of the area of application|Assessment of the skin thickening of the area of application|Assessment of the swelling of the area of application,1,10
388,Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting,1,10
389,Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse,1,10
390,Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.|Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment|Changes in PENN score are considerate for the motor and sensory functions evaluation|Changes in VAS score are considerate for quantification of pain|Changes in BDS score are considerate for the Assessment of the functional status|Changes in GEFFNER score are considerate for the Assessment of the functional status,1,10
391,Maximum tolerated dose (MTD)|Number Of Adverse Events related to the treatment|Overall Survival improvement (OS)|Progression Free Survival (PFS)|Tumor assessment in regard to the investigational drug based on the RANO criteria|Clinical efficacy assessment,1,10
392,"Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)",1,10
393,Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):,1,10
394,Primary Objective|Secondary Objective,1,10
395,Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.|Change in quality of life|Changes in exercise capacity|Changes in plasma inflammatory markers,1,10
396,Occurrence and rate of dose limiting toxicity|Rate of death|Occurrence of Other Severe Complications of Prematurity|Need for Ventilatory Support|Changes in Hemodynamics|Feasibility: Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Griffiths-II and Bayley Scales of Infant Development (2nd edition)|Long-term Safety Follow-Up,1,10
397,"Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion",1,9
398,To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI),1,9
399,Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video,1,9
400,"Number of subjects with Adverse Drug Reaction|Neurological development test outcome from the subjects who were treated with Pneumostem®, compared with the patients who suffered from the same conditions but not treated with Pneumostem®|Growth",1,9
401,The incidence and frequency of adverse events related to administration of UMC119-06.|Changes in Forced Vital Capacity (FVC).|Changes in Forced Expiratory Volume in One Second (FEV1).|Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).|Changes in exercise performance using 6-min walk test (6MWT).|Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).|Changes in modified medical research council (mMRC) -dyspnea scale.,1,9
402,Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change,1,9
403,unsuspected death or anaphylactic shock|Death or hydrocephalus required shunt operation,1,9
404,Number of adverse events as a measure of safety and tolerability,1,9
405,Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge,1,9
406,Toxicity of allogeneic MSC injection according to CTCAE|Toxicity of allogeneic MSC injection according to CTCAE Month 1|Toxicity of allogeneic MSC injection according to CTCAE Month 3|Toxicity of allogeneic MSC injection according to CTCAE Month 6|Toxicity of allogeneic MSC injection according to CTCAE Month 12|Proportion of subjects with Clinical Response Month 3|Proportion of subjects with Clinical Response Month 6|Proportion of subjects with Clinical Response Month 9|Proportion of subjects with Clinical Response Month 12|Disease activity measured by the BILAG index Month 3|Disease activity measured by SELENA-SLEDAI Month 3|Disease activity measured by SELENA-SLEDAI Month 6|Disease activity measured by the BILAG index Month 6|Disease activity measured by the BILAG index Month 9|Disease activity measured by SELENA-SLEDAI Month 9|Disease activity measured by the BILAG index Month 12|Disease activity measured by SELENA-SLEDAI Month 12|SRI Month 3|SRI Month 6|SRI Month 9|SRI Month 12|comorbidities Month 3|comorbidities Month 6|comorbidities Month 9|comorbidities Month 12|Quality of life Month SF-36 Month 3|Quality of life EQ-5D Month 3|Quality of life Month SF-36 Month 6|Quality of life EQ-5D Month 6|Quality of life Month SF-36 Month 9|Quality of life EQ-5D Month 9|Quality of life Month SF-36 Month 12|Quality of life EQ-5D Month 12|Steroids Month 3|Steroids Month 6|Steroids Month 9|Steroids Month 12,1,10
407,Intrauterine adhesion patients efficacy evaluation|Incision lacuna and incision diverticulum patients efficacy evaluation|Ultrasound of uterus evaluation|Hysteroscopy evaluation|Pain score,1,10
408,Absence of lung deficits during the procedure and/or in the 4 months follow-up|Quality of Life|Pulmonary function|Inflammation,1,10
409,Disease-related clinical reactions|PFS,1,10
410,"Rate of serious and non-serious adverse events related to the procedure.|Number of new fractures|Pain, measured by Visual Analog Scale|Functionality, measured by Oswestry Disability Questionnaire|Quality of Life, measured by EuroQoL-5D test|Bone resorption, measured by biochemical index|Bone formation, measured by biochemical index|Bone metabolism, measured by biochemical index|Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)|Bone structure, measured by histomorphometric evaluation|Trabecular bone density measured by quantitative computed tomography of the radius",1,10
411,Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score,1,10
412,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Drug Reduction Rate test|Tractography|Blood-based biomarkers|Cerebrospinal Fluid (CSF) based biomarkers,1,10
413,"• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.",1,10
414,"Safety evaluation through vital signs, the results of clinical lab tests and adverse events|Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence",1,10
415,To evaluate number of paticipants with adverse events|GVHD clinical response,1,10
416,Alveolar bone defect|Tooth mobility,1,10
417,Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody,1,10
418,"Incidence of treatment-emergent adverse events|Extent and severity of a patient's spinal cord injury|Motor electrophysiology assessment|Somatosensory electrophysiology assessment|Electrical nerve stimulation on pain perception|Mictional dysfunction|Anal sphincter integrity|Neuropathic pain|Spasticity|Functionality|Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)|Urinary disorder|Size injury|Presence of allogeneic cells|Immunology",1,10
419,Reduction of corticosteroid dose to ≤ 7.5 mg/day of prednisone or equivalent|Hematologic improvement without ongoing SLE treatment|Renal response improvement|Proportion of subjects who achieve a prednisone dose of ≤ 7.5mg/day or equivalent|Proportion of subjects achieving Low Level Disease Activity State|Proportion of subjects with ≥ 4 point reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 4 having SLE responder index 4 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 5 having SLE responder index 5 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 6 having SLE responder index 6 (SRI6)|Time to first severe modified SLE Flare Index (SFI) flare|Change from baseline of hematologic parameters|Time to first hematologic flare|Change in baseline of renal function parameters|Time to event for each of the individual components of treatment failure|Time to complete remission|Time to first renal flare,1,10
420,Change in WOMAC (Western Ontario and McMaster Universities)score|Change from baseline in cartilage thickness at 6 months by MRI|Knee pain relief (WOMAC and Lequesne scores)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray),1,10
421,Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin,1,10
422,"Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness",1,10
423,"Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples",1,10
424,To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.|To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC|To document survival post MSC infusion,1,10
425,Evaluation of the safety and tolerability of the intra articular injection|Assessment of the efficacy of intra-articular injection of ATMSC,1,10
426,"Clinical assessment of nature, incidence, and severity of adverse events (AEs)|Self-reported assessment of nature, incidence, and severity of AEs|Study personnel assessment of nature, incidence, and severity of AEs|Global Health Scale (GHS)|Visual Analog Scale (VAS) - back and leg pain|Oswestry Disability Index (ODI)|Patient Health Questionnaire-4 (PHQ-4)|Narcotic Use Questionnaire|Work Status Questionnaire|PROMIS-CAT|Changes from Baseline evaluated by MRI|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide",1,10
427,Adverse Event|Incidence of injection-related pain according to VAS scale (0-100mm)|Incidence of injection-related sinovitis according to effusion grading scale of knee joint|Pain reduction|Disability reduction|Percentage of responders,1,10
428,Dose Limiting Toxicity|Wound size evaluation,1,10
429,"Evaluate safety and feasibility of transendocardial injection using the NogaStar XP Mapping Catheter with the MyostarTM Left Ventricular Injection Catheter of autologous MSC in subjects with chronic myocardial ischemia and left ventricular dysfunction|Change from baseline in SF-36, VO2max, 6 min walk test, and the NYHA, CCS Classifications Effect related to cardiac function",1,10
430,evaluation the best passage of MSC culture by CD49 surface marker,1,10
431,Clinical deterioration|Serious Adverse Events|ICU transfer|Respiratory support|Hospital mortality and length of stay|Ventilator free days|28 day mortality,1,10
432,Number of participants with adverse reactions for 84 days after treatment|Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age|Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)|Hospital Re-admission between 84 days after treatment until 20 months of corrected age|Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age,1,12
433,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Functional motor power outcome pre-surgery|Functional motor power outcome at 12 months follow-up|Initial elbow flexion MRC grade 1 (in months)|Initial elbow flexion MRC grade 3 (in months)|Pain outcome pre-surgery|Pain outcome at 12 months follow-up|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at 12 months follow-up|Short Form-36 (SF-36) score pre-surgery|Short Form-36 (SF-36) score at 12 months follow-up",1,24
434,"Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip",1,24
435,Change in Visual Analog Pain Scale (VAS) Over Time|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Over Time|Change in Knee Injury and Osteoarthritis Outcomes Score (KOOS) Over Time,1,75
436,Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow,1,74
437,Proportion of subjects with complete target wound closure,1,74
438,Disease remission|Disease Improvement|Improvement in Quality of Life (IBDQ)|Number of Adverse events as a measure of safety|Infusional toxicity as a measure of safety and tolerability,1,73
439,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline,1,72
440,Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization,1,72
441,"Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)|Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)|MELD Score|Child-Pugh grade|Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)|Visual Inspection (Liver volume, Fibroscan)",1,72
442,Incidence of Treatment-Emergent Serious Adverse Events|Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.|Number of Participants with Changes in Echocardiography Overall Assessment|Number of Participants with Changes to overall assessment of Electrocardiogram|Time to recovery of Sp02|Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.|Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.|Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis|Immunity|Change in Imaging via X-ray|Change in Imaging via Computerized Tomography,1,70
443,Efficacy-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) assessment|Efficacy-Visual Analogue Scale (VAS) assessment|Efficacy-SF-36 Quality of Life (QoL) health survey questionnaire|Efficacy-Whole-Organ Magnetic Resonance Imaging Score (WORMS)|Efficacy-knee joint space width (JSW)|Efficacy-synovial fluid|Efficacy-rescue medication|Safety-AE/SAE based on NCI-CTCAE v5.0|Safety-vital signs|Safety-laboratory examination|Safety-physical examination,1,70
444,Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis,1,70
445,"Incidence of composite serious adverse events (Phase I)|Patients alive without grade 3, 4 infusional toxicity (Phase II)|Patients alive with grade 3 or 4 infusional toxicity (Phase II)|Patients not alive (Phase II)|Proportion of successfully extubated patients who present intubated on ventilator support (Phase I)|Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Overall survival rate (Phase I)|Survival rate in patients who present intubated on ventilator support (Phase I)|Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Phase I)|Clinical parameters (Phase I)|Oxygenation parameters (Phase I)|Respiratory parameters (Phase I)|Laboratory markers (Phase I)|Hospitalization stay (Phase I)|Intensive care unit stay (Phase I)|Incidence of infusion-related adverse events (Phase I)",1,70
446,"safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)",1,69
447,Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA|Intubation duration|Incidence of BPD|Survival rate|Duration of ventilator dependence|Duration of CPAP treatment|Postnatal steroid use (%) for the purpose of ventilator weaning|Cumulative duration of oxygen use|Incidence of Retinopathy of Prematurity (ROP) of Grade III or more|Retinopathy of Prematurity (ROP) that require treatment with avastin or laser|Growth velocity (Z-score)|Length of stay prior to the first discharge from the hospital|Incidence of adverse events|Clinically significant laboratory findings|Incidence of pneumothorax that require intubation|Incidence of moderate to severe pulmonary hemorrhage|Incidence of intraventricular hemorrhage of grade 3 or more,1,69
448,Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide,1,66
449,Change from baseline knee pain measured with a Visual Analogue Scale (VAS) at 1 year|Change from baseline functionality measured with Knee Injury and Osteoarthritis Outcome Score (KOOS) at 1 year|Change from baseline quality of life measured with SF-36 questionnaire at 1 year.|Change from baseline disability measured with WHODAS 2.0 questionnaire at 1 year.|Change from baseline joint cartilage characteristics measured with Magnetic Resonance Imaging at 1 year.,1,66
450,Follicular development rate|Changes in blood flow index in the ovary|Clinical pregnancy rate,1,66
451,Treatment-related serious adverse events (tSAEs)|Change in clinical status at day 14,1,66
452,"SOFA score|Number of living days without catecholamines|Number of living days without mechanical ventilation|Number of living days without dialysis|Duration of residence time in recovery unit|Mortality, across all causes|Administration safety (i.e. side effects)",1,66
453,Tissue Collection,1,65
454,Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels,1,65
455,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT.",1,65
456,Proportions of subjects who achieved complete wound closure.|Time to initial complete wound closure between the 2 groups.|Changes in wound size compared to baseline between the 2 groups.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.|Durability of complete wound closure for the additional 24 weeks.,1,64
457,C-peptide area under the concentration curve (AUC) response (MMTT)|Peak C-peptide response (MMTT)|Basal C-peptide response|Total daily insulin dose (units/kg)|Glycosylated hemoglobin (HbA1c) levels|Number of severe and documented hypoglycemic events|Changes in levels of glutamic acid decarboxylase (GAD) or islet antigen 2 (IA-2) autoantibodies,1,63
458,"Alveolar bone filling rate|Serious adverse events|Non serious adverse events|Bone Tissue Engineering With Dental Pulp Stem Cells for Alveolar Cleft Repair|Position of the canine tooth and formation of dental root|Patient-reported outcome (PRO, including appearance, fuction and quality of life)",1,62
459,Correlation between NF-кB dependent-proinflammation markers and osteoblast-specific gene expression in the MSC to measure the effects of NF-кB dependent-proinflammation on differentiation potential toward osteoblast in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and apoptotic marker expression in the MSC to measure effects of NF-кB dependent-proinflammation on cellular apoptosis in type 2 diabetes.|Correlation between NF-кB dependent-proinflammation markers and the expression of RAGE and its downstream signals in the MSC to measure effects of NF-кB dependent-proinflammation on cellular RAGE activation in type 2 diabetes.,1,75
460,Two Co-Primary Efficacy Endpoints|Secondary Efficacy Endpoints|Secondary Safety Endpoints,1,75
461,Gut microbiome composition|Infectious complications after transplantation|Organ or tissue rejection,1,90
462,Healing time|Wound shrinkage rate,1,76
463,LVEF amount of change|Infarct size amount of change|Left ventricle end systolic size change|Left ventricular end-diastolic size change|Incidence of critical heart events|Heart rate variability change amount|Left ventricular local wall movement disorder index change|N-terminal pro-brain natriuretic peptide (NT-proBNP) change,1,90
464,Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations,1,90
465,"Relief of the rest pain|Healing of ulcerations or reduction of ulcer area in the target limb|Pain free walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Increase in transcutaneous partial oxygen pressure (TcPO2)|Quality of life by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)|The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).|Assessment of clinical laboratory parameters|Physical examination findings and assessment of vital signs|Assessment of electrocardiogram (ECG) parameters",1,90
466,Vancouver Scar Scale score|Erythema|Pigmentation|Scar Thickness and Uniformity|Subject's satisfaction,1,90
467,Change of Vancouver Scar Scale (VSS)|Wound healing status|Erythema measured by reflectance|Pigmentation measured by reflectance|Scar Thickness and Uniformity|Change of scar area|Immunoglobulin concentrations in breast milk|Subject's satisfaction|Adverse events occurrence,1,90
468,Antral follicular count (AFC) serum levels|anti-Müllerian hormone (AMH) serum levels|Regular menstruation and/or pregnancy,1,86
469,Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture.|Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union.|Comparison of the rate of complications between the 2 groups.|Economic impact study.,1,85
470,Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism,1,84
471,Change in mean total hair density (hair/cm2)|Compare visual assessment before and after cosmetic treatment|Change in mean Telogen hair density|Change in mean Anagen hair density|Change in hair growth speed|Change in hair diameter,1,84
472,Crohn's disease activity index|Harvey-Bradshaw index|Corticosteroid dosage,1,82
473,Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days,1,82
474,Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:,1,81
475,The incidence of serious adverse events.|Number to patients with All-Cause Mortality at 28 days|Ventilator-free days at 28days|Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.,1,81
476,"Incidence of Treatment-Emergent Adverse Events (Safety Evaluation)|Imaging indicator: Quantitative analysis of CT density histograms|Clinical Indicator 1: change in blood gas analysis|Clinical Indicator 2: change in MRC chronic dyspnea scale|Clinical Indicator 3: change in St. George's Respiratory Questionnaire (SGRQ) scale|Immunological Indicator in serum : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in lavage fluid : response level of CD4+ T lymphocyte subsets (Th1/Th2/Th17)|Immunological Indicator in serum : expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Immunological Indicator in lavage fluid: expression levels of various cytokines including TNF-α, IL1-β, MIP-1α, TIMP1, PDGF|Fibrosis Indicators in serum: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|Fibrosis Indicators in lavage fluid: expression levels of TGF-β1, hydroxyproline, MMP2, MMP9|self-evaluation",1,80
477,ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change)|Treatment related Adverse Events,1,80
478,The difference in the renal function between the two groups (MSC treatment group vs placebo control group) within 28 days after receiving MSC/ placebo treatment|Overall survival within 28 days after receiving MSC/ placebo treatment|Overall survival within 3 months after receiving MSC/ placebo treatment|Renal replacement therapy (RRT) dependent within 3 months after receiving MSC/ placebo treatment|Complete renal recovery within 3 months after receiving MSC/ placebo treatment|Partial renal recovery within 3 months after receiving MSC/ placebo treatment|ICU and hospitalization duration of stay among all AKI patients within 3 months after receiving MSC/ placebo treatment|Adverse events within 3 months after receiving MSC/ placebo treatment,1,80
479,The improvement of the fusion of the posterolateral fusion measured on X-rays|The improvement of the fusion of the posterolateral fusion measured on X-rays and CT scans.,1,80
480,Absolute changes in global LVEF by SPECT|Changes in left ventricular end-diastolic volume (LVEDV)|Changes in left ventricular end-systolic volume (LVESV)|Changes in regional wall motion score index (WMSI) by Echocardiography|Major adverse cardiac event (MACE),1,80
481,Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue|Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog|Changes in Visual Analog Scale of Neurological Symptoms. - Headache|Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities.|AEs of special interest (serious or non-serious) - infections.|AEs of special interest (serious or non-serious) - hypersensitivities.|Changes in Laboratory values. - CBC.|Changes in Laboratory values. - CMP.|Changes in Laboratory values. - Coagulation Panel.|Changes in Vital Signs. - Respiratory Rate (breaths per minute)|Changes in Vital Signs. - Heart Rate (beats per minute)|Changes in Vital Signs. - Body Temperature (Fahrenheit )|Changes in Vital Signs. - Blood Pressure (mmHg)|Changes in Weight in lb.|Changes in Physical examination results. - General|Changes in Physical examination results. - Body Systems|Changes in Subject's energy - Fatigue Assessment form.|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity|Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough|Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches|Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain|Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire|Changes in Subject's level of depression - PHQ 9 scale.,1,80
482,Safety/efficacy,1,80
483,Gross Motor Function|Cognitive Function|Chemical Marker,1,78
484,Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR])|Percentage of Participants who Achieve Complete Response (CR) or Partial Response (PR) (i.e. Overall Response Rate [ORR]).|Organ-specific Assessments|Patient-Reported Outcomes|Clinician-Assessed Global Rating/Scale|Failure-free Survival,1,77
485,Change in UMSARS total (= UMSARS I + UMSARS II) score|Change in UMSARS I score|Change in UMSARS II score|Change in modified UMSARS score|Change in COMPASS select score|Rate of atrophy of selected brain regions,1,76
486,"The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause|Falls Efficacy Scale-International (FES-I)|Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:|Rate of decline in Aging Frailty status as assessed by the 6 minute walk test|Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)|Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test|Rate of decline in Aging Frailty status as assessed by the Weight Loss|Rate of decline in Aging Frailty status as assessed by the Handgrip Test",1,62
487,Number of Participants with Adverse Events (AEs)|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) %predicted at Year 1 and Year 2|Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume to Forced Vital Capacity Ratio (FEV1/FVC) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) %predicted at Year 1 and Year 2|Change from Baseline in Alveolar Volume (VA) at Year 1 and Year 2|Change from Baseline in Diffusing capacity of the lung for carbon monoxide to Alveolar Volume ratio (DLCO/VA)at Year 1 and Year 2|Change from Baseline in Functional residual capacity (FRC) at Month 6|Change from Baseline in Total Lung Capacity (TLC) at Month 6|Change from Baseline in Residual Volume (RV) at Month 6|Change from Baseline in Airway Resistance (RAW) at Month 6|Change from Baseline in 6-Minute Walk Test at Year 1 and Year 2|Change from Baseline in Borg Dyspnea Scale at Year 2|Change from Baseline in Health-related quality of life: St George's Respiratory Questionnaire (SGRQ) at Year 1 and Year 2|Change from Baseline in Physician Global Assessment Scale at Year 1 and Year 2|Time to COPD Exacerbation|Number of COPD Exacerbations|Change from Baseline in Pulmonary Hypertension at Month 6|Change from Baseline in Systemic Inflammation at Year 1 and Year 2,1,62
488,"Respiratory outcome: readmission rate and duration of the hospital stay due to respiratory infection|Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)|Number of admissions to Emergency Room|Survival|Growth measured by Z-score|Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy|Deafness or Blindness|Number of adverse events|Significant changes in vital signs|Significant changes in physical exam",1,62
489,Primary objective of the study is to assess the safety and tolerability of MPC therapy,1,61
490,"The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.|The secondary objectives are to explore functional efficacy for subsequent study design.",1,60
491,Safety of intravenously infused UCT-MSC suspension|Pulmonary function test to evaluate the improvement of respiratory function|Radiography to evaluate the improvement of respiratory function|6-minute walk to evaluate the improvement of respiratory function|Decrease on days of non-invasive mechanical ventilation|Biochemical tests to evaluate the improvement of laboratory parameters|Blood count to evaluate the improvement of laboratory parameters|Viral load to evaluate the improvement of laboratory parameters|Cytokine dosage to evaluate inflammatory parameters|Decrease in hospital stay|Computed tomography score to evaluate the improvement of pulmonary function|Reduction in the percentage of intubated patients|Decrease in mortality,1,60
492,"Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline",1,60
493,Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels,1,60
494,Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h,1,60
495,Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R),1,60
496,Respiratory outcome: Number of hospitalizations|Mortality|Growth measured by Z-score|Neurological developmental status: Korean Developmental Screening Test for infants and children(K-DST)|Deafness or Blindness|Bayley Scales of Infant and Toddler Development (Third Edition)|Gross Motor Function Classification System for Cerebral Palsy|Number of adverse events|Number of admissions to Emergency Room (ER)|Medical treatment records,1,60
497,Improvements in left ventricular function|Clinical improvements,1,59
498,Proportion of re-epithelialization|Time to re-epithelialization|Number of Participants with Adverse Events as a Measure of Safety and Tolerability,1,59
499,Dose limiting Adverse events|Severe infusion reactions|Grade 2 elevated creatinine,1,58
500,Maximum tolerated dose (MTD) (Phase I)|Number and severity of adverse events (Phase I)|Overall toxicity incidence (Phase I)|Toxicity profiles by dose level and patient (Phase I)|Proportion of patients alive at 12 months (Phase II)|Tumor response (Phase II)|Rate of progression free survival (Phase II)|Overall survival (Phase II)|Progression free survival (Phase II)|Maximum grade for each type of toxicity (Phase II),1,57
501,"Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure",1,56
502,Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9,1,56
503,Comparison of treatment adverse event rates|Concomitant Medications|Visual Analog Scale,1,55
504,"Measure and report the number of participants with treatment-related-adverse events as assessed by CTCAE v4.0; for patients receiving ARDOXSO™, perinatal MSC-derived exosome therapy.|Tabulate and report the number of IMV days for patients receiving ARDOXSO™ perinatal MSC-derived exosome therapy.|Analyze and report organ failure, associated with ICU mortality in participants confirmed with SARS-CoV2 infection, receiving ARDOXSO™ as an interventional exosome therapy.|Record and analyze respiratory measures (Berlin Score/PEEP) following treatment regime.",1,55
505,Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.,1,55
506,Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9,1,55
507,"Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy|Overall Survival (OS) Rate at Day 100 Post Initiation of Therapy|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Responder Status at Day 28|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Baseline aGVHD Grade|OS Rate at Day 100 Post Initiation of Therapy, Stratified by Organ Involvement|OR Rate at Day 56 and 100 Post Initiation of Therapy",1,55
508,Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product|Efficacy of the PMSC-ECM Product,1,55
509,Adverse Events and Sever Adverse Events|Efficacy of Celltex AdMSCs,1,54
510,"Safety and tolerability: Adverse events (AEs)|Safety and tolerability: 12-lead electrocardiogram (ECG)|Safety and tolerability: Laboratory examinations|Safety and tolerability: Physical examinations|Safety and tolerability: Vital signs|Preliminary efficacy: Changes in Visual Analogue Scale (VAS) for pain compared to baseline|Preliminary efficacy: Changes in Knee injury and Osteoarthritis Outcome Score (KOOS) compared to baseline|Preliminary efficacy: Change in EuroQoL 5 Dimension 5 Level test (EQ-5D-5L) compared to baseline|Preliminary efficacy: Change in 40 m fast paced walk test compared to baseline|Preliminary efficacy: Change in cartilage structure compared to baseline, based on MRI assessment of cartilage volume and composition|Preliminary efficacy: Change in whole knee health compared to baseline, based on MRI assessment by the MRI Osteoarthritis Knee Score (MOAKS)|Preliminary efficacy: Change in inflammatory activity compared to baseline, based on MRI assessment of synovial thickness and synovial blood flow|Preliminary efficacy: Changes in joint space narrowing based on x-ray compared to baseline",1,54
511,The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline,1,54
512,WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Recording of Adverse Events and Serious Adverse Events,1,53
513,vancouver scale,1,60
514,Adverse events and serious adverse events rate|Rate of clinical significant changes in laboratory|Rate of abnormal neurological physical examination results|Rate of imaging changes|Change of NIHSS scores|Change of BI scores|Change of mRS scores|Change of MMSE scores|Change of GDS scores,1,60
515,Safety of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy|Efficacy of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy,1,60
516,"Comparison of treatment adverse event rates between the 0.5, 1.6 and 5.0 million mesenchymal stem cells per kilogram dose cohorts and placebo groups.",1,60
517,Meniscal Volume|Quality of Life Questionnaire|Visual Analog Scale (VAS)|Lysholm Knee Scale|Safety Assessment Adverse Event|Safety Assessment Immunological|Safety Assessment Laboratory|Safety Assessment Physical Exam|Safety Assessment Magnetic Resonance Imaging (MRI),1,60
518,Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months,1,60
519,Increased distance on Six Minute Walk Test (6MWT)|Incidence of Serious Adverse Events (SAEs)|EuroQol-5D (EQ-5D)|Medical Research Council (MRC) Dyspnea Scale,1,60
520,clinical|radiological proof,1,60
521,Osteogenic Potential of Mesenchymal Stem Cells,1,60
522,Kellgren-Lawrence Grading Scale|Assessment of Preoperative Cartilage Defect Severity (AMADEUS)|Lysholm scoring|The international knee documentation committee (IKDC) knee evaluation form|Visual Analogue Scale/Score（VAS）,1,60
523,Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.,1,60
524,Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline,1,60
525,The quantity of mesenchymal stem cells present in the synovial fluid of patients with precollapse ON of the femoral head and postcollapse ON of the femoral head compared to patients without intraarticular hip pathology.,1,60
526,"Changes of oxygenation index (PaO2/FiO2) ,blood gas test|Detection of TNF-α levels, IL-10 levels|Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).|Changes of c-reactive protein and calcitonin",1,60
527,All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation,1,60
528,"1. Changes in the total score MDS-UPDRS Part II.|2. Incidence of treatment-emergent Adverse Event (TEAEs).|3. Incidence of treatment-emergent Serious Adverse Events (SAEs).|4. AEs of special interest (serious or non-serious) - thromboembolic events.|5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities|6. AEs of special interest (serious or non-serious) - infections|7. AEs of special interest (serious or non-serious) - hypersensitivities.|8. Laboratory value Complete Blood Count (CBC)|9. Laboratory values Chemistry Metabolic Panel (CMP)|10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern|11. Vital signs. - Respiratory Rate (breaths per minute)|12. Vital signs. - Heart Rate (beats per minute)|13. Vital signs. - Body Temperature (Fahrenheit )|14. Vital signs. - Blood Pressure (mmHg)|15. Weight in lb.|16. Physical examination results. General|17. Physical examination results. Body Systems.|18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.|19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.|20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.|21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.|22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).|23. Changes in Parkinson's disease fatigue scale (PFS-16)|24. Changes in Parkinson's disease Questionnaire (PDQ-39).|25. Changes in Visual Analog Scale for Pain.|26. Changes in Visual Analog Scale for Muscle spasms.|27. Changes in Dosage of medications taken to treat Parkinson's disease.",1,60
529,pain|physical activity|walking distance|Imaging,1,60
530,12 month Change in C-peptide area under the curve after a 2-hour MMTT|6 Month Change in C-Peptide area under the curve after a 2-hour MMTT|6 Month peak C-peptide after a 2-hour MMTT|1 year peak C-peptide after a 2-hour MMTT|Change in 24-hour insulin dose per kilogram between baseline and 1 year measurements,1,60
531,Isolation and Expansion of Mesenchymal Stem Cells|Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments,1,60
532,Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.|Modified Rankin Scale|National Institute of Health stroke scale|Mini-mental State Examination|Barthel Index|Geriatric Depression Scale,1,60
533,Exercise test|Clinical evaluation,1,60
534,survival after intervention|sequential organ failure assessment score|interleukin-6|The number of allergic reactions|The number of people who get cancer|the effects on kidney function|the effects on liver function|the effects on lung function|the effects on coagulation function|the effects on central nervous system,1,60
535,"Proportion of patients with deep ulcer healing|Proportion of patients with stricture healing|Proportion of patients with complex perianal fistula healing|Safety assessed by the incidence of treatment-emergent adverse events during the study period|Evolution of clinical disease activity index|Evolution of Short health scale (quality of life)|Evolution of the Lemann Index (measuring cumulated intestinal damage in Crohn's disease)|Evolution of the "" Group of Therapeutic Study of Inflammatory Disorders of the Digestive Tube"" obstructive score for Crohn Disease strictures",1,60
536,"Change in proportions of subjects with combined remission of treated perianal fistula between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula clinical remission between the AVB-114 and standard of care groups.|Change in the means of durability of clinical remission between the AVB-114 and standard of care groups.|Change in means of time to clinical remission between the AVB-114 and standard of care groups.|Change in proportions of subjects with fistula relapse between the AVB-114 and standard of care groups.|Change in means of time to fistula relapse between the AVB-114 and standard of care groups.|Change in proportions of radiologic response of treated fistula between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the Perianal Disease Activity Index (PDAI) between the AVB-114 and standard of care groups.|Change in means of disease activity index scores using the short Crohn's Disease Activity Index (sCDAI) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Euroqol 5 Diumention 5, level measure of health status (Eq-5Q-5L) between the AVB-114 and standard of care groups.|Change in means of patient quality of life assessment scores using the Inflammatory Bowel Disease Questionnaire (IBDQ) between the AVB-114 and standard of care groups.|Change in patient assessment of impact to daily functionality related to treated fistula between the AVB-114 and standard of care groups.|Change in the evaluations of patient care trajectory related to treated fistula between the AVB-114 and standard of care groups.|Change in number of adverse events between the AVB-114 and standard of care groups.|Change in number of serious adverse events between the AVB-114 and standard of care groups.",1,60
537,The relapse-free period|The need for surgical intervention|The need for the use of basic drug therapy|Adverse effects associated with the therapy,1,60
538,Time to clinical improvement (days)|Increase in Lymphocytes counts|Decrease in D-dimer|Decrease in LDH level|Decrease in Ferritin concentration|Decrease in C-reactive protein|Adverse events,1,60
539,"Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline|Change amount of WOMAC total score at post-dose 24 weeks from the baseline|Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline|Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline|Change in T2 mapping at post-dose 52 weeks from the baseline|Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline|Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.|Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks",1,90
540,Change in VO2max|Left ventricular viability|NYHA/CCS class|Quality of life (Minnesota questionnaire)|VO2 max|6'walking-test|Echocardiography|Myocardial perfusion imaging|BNP blood test,1,90
541,"Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.",1,24
542,"Evaluation of surviva|Evaluation of proliferation|Evaluation of apoptosis, phenotype, function of cells|Evaluation of phenotype",1,200
543,Transplant free survival (TFS)|Survival rate|Change amount of Child-Pugh score|Change amount of MELD score|Change amount of Liver function test|Change amount of Fibrosis-4|Change amount of FibroScanⓇ|Change amount of EQ-5D|Change amount of EQ-VAS,1,200
544,"Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.",1,200
545,"Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14",1,200
546,Any composite of major adverse cardiovascular events|Checking patient LVEF|Checking patient infarct size|checking patient perfusion defect.|Coronary disease|Coronary congestive heart failure|Coronary changes in hsCRP,1,200
547,Liver function|The incidence of serious complications|The incidence of adverse events|Disease-free survival time|Incidence of hepatocellular carcinoma (HCC) events,1,200
548,"Nature, incidence and severity of adverse events (AEs)|Change in Numerical Rating Scale (NRS)|Change in joint swelling|Change in the 36-Item Short Form Survey (SF-36)|Change in Knee injury and Osteoarthritis Outcome Score (KOOS)|Change in the International Knee Documentation Committee (IKDC 2000)|Change in cartilage morphology|Change in cartilage T2 relaxation time mapping in MRI|Changes in bone marrow edema-like lesions (BMLs)|Change in weight distribution on stable platform|Change in Range of motion (ROM)|Change in ultrasonographic findings in knee joint",1,200
549,Proportion of modified Rankin Scale (mRS) 0-2|changes in Fugl-Meyer scale|changes in Purdue hand function test|changes in box and block test|Proportion of modified Rankin Scale (mRS) 0-1|changes in the national institutes of health stroke scale (NIHSS)|changes in Mini-mental State Examination (MMSE) score|changes in Montreal Cognitive Assessment (MoCA) score|The changes of head images|changes in some serum biomarkers,1,200
550,Percentage of Participants with Treatment Success|Percentage of Participants with Overall Response|Percentage of Participants with Induction of a 2-grade decrease in (Graft Versus Host Disease) GVHD by Study Day 28 with maintenance of a 2-grade decrease in GVHD through Study Day 56|Percentage of Participants with Induction of CR lasting for greater than or equal to 14 Days|Percentage of Participants with Induction of a CR after Study Day 28 and clinically managed with steroids with second line/escalation therapy through Study Day 56|Percentage of Participants with Induction of PR during the first 28 days|Time to achieve CR|Number of CR per organ|Total corticosteroid dose administered|Number of corticosteroid-related complications|Number of Infectious complications|Number of Days of Hospitalization|Average Daily Corticosteroid Dose,1,192
551,Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy|Cumulative relapse incidence|cumulative incidence of chronic GVHD at one year|Cumulative Incidence of Infectious Complications|Cumulative Incidence of lymphoproliferative disease,1,182
552,Total Atheroma Volume|MACE (Major Adverse Cardiovascular Events)-Free Survival|Per Cent of Fibro-fatty Component|Event Free Survival|Restenosis Rate|Late Definite Thrombosis|Coronary Vasomotion - Mean Lumen Diameter After Infusion of Acetylcholine 10-6 M|Per Cent Atheroma Volume|Target Lesion Revascularization|Per Cent of Fibrous Component|Per Cent of Necrotic Core|Per Cent of Calcium|Minimal Lumen Diameter|MACE|Cardiac Death|TLR (Target Lesion Revascularization)|TVR (Target Vessel Revascularization)|Mean Number of Membrane Defects on Membrane of Red Blood Cells,1,180
553,Oxygen requirement 3 days after transplantation|Oxygen requirement 7 days after transplantation|Duration of ventilator dependence|Incidence of severe BPD|Survival rate|Temperature|Heart rate|Respiratory rate|Duration of CPAP treatment|Percentage of participants treated with steroids for weaning from ventilator|Growth velocity (Z-score)|bronohoalveolar lavage (BAL) cytokine level|The severity of BPD in X-ray patterns,1,180
554,Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU,1,169
555,Incidence rate of biopsy-proven acute rejection and early renal function recovery|Patient and graft survival and prevalence of adverse events,1,165
556,Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure between the two groups|Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups|Change rates in wound size and depth compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations,1,164
557,Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale,1,164
558,"Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography.|Secondary endpoints: safety will be determined by the assessment of major adverse coronary events (MACE).",1,160
559,The safety of allogenic umbilical cord-derived mesenchymal stem cell administration for the treatment of hormone deficiency in male|Testosterone levels|Changes in sexual life quality using Aging Men Symptom (AMS)|Changes in sexual life quality through quantification of International Index of Erectile Function (IIEF)|Changes in sexual life quality through quantification of Sexual Quality of Life Questionnaire (SQoL-M),1,158
560,Short-term therapeutic effects of transplantation.|Long-term outcomes of transplantation.,1,158
561,ORR|OS|DFS|Response rate|EBV DNA-emia|CMV DNA-emia|PGF,1,152
562,Changes in cellular properties of mesenchymal stromal cells|Number of differential biomarkers in mesenchymal stromal cells,1,150
563,Change in bone width|Pain postoperatively in the two different treatments|Radiological examination of bone volume,1,150
564,Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo,1,150
565,Therapeutic Efficacy of Darvadstrocel-Clinical|Therapeutic Efficacy of Darvadstrocel-MRI|Quality of Life (QoL)|PATIENT REPORTED OUTCOMES (PROs)|Efficiency,1,150
566,"The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media",1,200
567,Can Stem Cells Predict Orthopaedic Outcomes?,1,203
568,Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events,1,91
569,Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score,1,210
570,survival|duration of hospitalization|Time to resolution of cytokine release storm|Time of viral clearance|Complications,1,600
571,"Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by left ventricular ejection fraction (LVEF [radionuclide ventriculography {RVG} or echocardiogram])|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - European Quality of Life (EuroQoL) 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBCs, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic blood pressure [BP], diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QT interval with Fridericia's correction (QTcF), heart rate-corrected QT interval (QTcB), QT, Q wave, R wave and S wave (QRS) complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data",1,566
572,Visual Acuity|Visual Fields|Optical Coherence Tomography (OCT),1,500
573,Change in Visual Analog Pain Scale (VAS-pain) Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Symptoms Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Activities of Daily Living (ADL) Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Sports and Recreation Function Subscale Score|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Quality of Life (QoL) Subscale Score|Change in EuroQuality of Life (EQ-5D-3L) Index Score|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) Score,1,480
574,The primary efficacy endpoint is overall 60-day mortality (due to any cause).,1,400
575,Disease remission (CDAI at or below 150)|Disease improvement (Reduction by at least 100 points in CDAI)|Improvement in quality of life (IBDQ)|Reduction in number of draining fistulas,1,330
576,"The primary end point was checking incidence of adverse events (AEs) within 12 months,|The secondary end point was measuring low attenuation plaque volume LAPV|The secondary end point was efficacy 2",1,300
577,"the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.|Any organ damage or safety concerns determined by SMAC 20 blood test.|Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|changes in joint images (X-ray or MRI) from the baseline",1,300
578,Change iHOT--33 Surveys from preoperative to various postoperative timepoints|Change HOS Surveys from preoperative to various postoperative timepoints|Change NAHS Surveys from preoperative to various postoperative timepoints|Change LEFS Surveys from preoperative to various postoperative timepoints|Change mHHS Surveys from preoperative to various postoperative timepoints|Change RAND-36 Surveys from preoperative to various postoperative timepoints|Degree of Improvement on Hip VAS Pain Score|Patient Satisfaction Questionnaires,1,300
579,Assessment of changes in International Standards for Neurological Classification of Spinal Cord Injury according to American Spine Injury Association|Assessment of changes in score of pain index using Short-form McGill Pain Questionnaire|Assessment of changes in score of activity of daily living|Assessment of changes in sensory evoked potentials and motor evoked potentials,1,300
580,Gross Motor Function Measure Score|Routine Blood Test and Biochemical Test,1,300
581,Combine remission of perianal fistulising Crohn's|Efficacy Assessment by week 24|Efficacy Assessment by week 52|Efficacy Assessment by week 104|Safety analysis throughout the study:,1,278
582,survival time|incidence of HCC events|The levels of serum albumin|The levels of serum total bilirubin|The levels of serum prothrombin activity|the levels of serum cholinesterase|complications,1,266
583,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,1,263
584,Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration|Overall Survival at 180 days Post First Infusion,1,260
585,Adverse Events|Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|WOMAC 3 subscale score|SF-36|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan,1,260
586,Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|Change of Visual Analog Scale (VAS) scores from baseline|WOMAC 3 subscale score|VAS score|KOOS|SF-36|IKDC|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan|Use of rescue medication,1,260
587,Magnetic Resonance Imaging in the 6th month after surgery|Magnetic Resonance Imaging in the 12th month after surgery|Magnetic Resonance Imaging in the 24th month after surgery|The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index|International knee documentation committee (IKDC) Knee Joint Score Sheet,1,252
588,Validity evaluation by detection the change of the VAS pain score relief rate for Lumbar disc pain of participants in different time point and compare with the VAS pain score before treatment|Observe treatment|Safety evaluation by detecting adverse events and serious adverse events|Safety evaluation by detecting Activated partial thromboplastin time (APTT)|Safety evaluation by detecting Prothrombin time (PT)|Safety evaluation by detecting Fibrinogen|Safety evaluation by detecting Thrombin time (TT),1,242
589,Incidence of Heart Failure|Change in Left Ventricular Function from base line|Cardiovascular Death|Composite outcome of cardiovascular death and heart failure incidence,1,240
590,Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 48 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events,1,240
591,Change in Model for End-Stage Liver Disease (MELD) score from baseline to 24th week|Change in MELD score from baseline to 96 weeks|Incidence of each complication associated with decompensated cirrhosis|liver transplant-free survival|Incidence of liver failure|plasma albumin (ALB)|plasma prealbumin (PALB)|total bilirubin (TBIL)|serum cholinesterase (CHE)|prothrombin activity (PA)|Child-Turcotte-Pugh (CTP) score|EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D)|ChronicLiver Disease Questionnaire (CLDQ)|Incidence of liver cancer|Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events,1,240
592,Change from Baseline in Cardiac Magnetic Resonance (CMR) imaging-determined End Systolic Volume (ESV) at Month 3|Left Ventricular End Systolic Volume|Infarct Size|Left Ventricular Ejection Fraction|Left Ventricular End Diastolic Volume|Number of Participants with Ventricular Arrhythmias|Duke Activity Status Index (DASI) Assessment|New York Heart Association (NYHA) Congestive Heart Failure Classification Status|Maximal Symptom-limited Exercise Test (Treadmill)|Number of Participants with Major Adverse Cardiac Events (MACE)|Overall Survival|Number of Participants with Adverse Events,1,220
593,Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score|Visual Analog Scale (VAS) score|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)|Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|International Knee Documentation Committee (IKDC) score|36-Item Short Form health survey questionnaires (SF-36) score|Structural changes in knee joint|Kellgren-Lawrence grade|Number and amount of rescue medication use,1,140
594,changes in womac score|changes in cartilage thickness as assessed on 1.5 T MRI|changes in joint space width,1,140
595,Fusion Rate (%)(as determined by CT assessment)|Radiographic outcome assessments|Functional outcome measurements,1,140
596,Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs,1,136
597,The efficacy of umbilical cord mesenchymal stem cells in Chinese adults with T2D|Other efficacy parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D|safety parameter of umbilical-cord mesenchymal stem cells in Chinese adults with T2D,1,103
598,American Spinal Injury Association (ASIA) Total Score at the Fourth Follow-up|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score at the Fourth Follow-up|American Spinal Injury Association (ASIA) Total Score|SCI Functional Rating Scale of the International Association of Neurorestoratology (IANR-SCIFRS) Total Score|International Standards to Document Remaining Autonomic Function After Spinal Cord Injury (ISAFSCI) Score|Penn Scale|Modified Ashworth Scale|Geffner Scale|Neurogenic Bowel Dysfunction (NBD) Scale|Residual Urine Volume,1,102
599,ICRS-Cartilage Repair Assessment Total Score|ICRS-Cartilage Repair Assessment Overall Grade|Improvement degree of Cartilage Repair by MRI|Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)|Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)|Degree of Functional improvement in Tegner activity score|Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)|Degree of pain improvement in 100 mm VAS(Visual Analogue Scale),1,102
600,"Frequency of dose limiting adverse events|Modified Rankin Scale (mRS) to measure the prognosis|National institute of Health Stroke Scale (NIHSS) to measure stroke recovery|Barthel Index (BI) to evaluate the self-care ability|Rate of muscle strength level of the hemiplegic limb|Mortality rate|Change in Glasgow coma scale (GCS) score|Change in Glasgow outcome scale (GOS) score|MRI (T1, T2, Flair, DWI) scanning",1,100
601,International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis,1,100
602,Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI),1,100
603,American Shoulder and Elbow Surgeons (ASES) Score|Magnetic Resonance Imaging (MRI) Scan|Functional Outcomes - Shoulder Exam|Patient Centered Outcomes - Shoulder Survey,1,100
604,Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage,1,100
605,death|Bayley Scales of Infant Development,1,100
606,Signal to Noise Quotient|Side to side difference in anterior tibial translation|Patient reported outcomes- Tegner Score|Patient reported outcomes- Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)|Patient reported outcomes- International Knee Documentation Committee (IKDC) Score,1,100
607,"Change in lesion proportion (%) of full lung volume from baseline to day 28.|Change in lesion proportion (%) of full lung volume from baseline to day 10 and 90|Change in consolidation lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Change in ground-glass lesion proportion (%) of full lung volume from baseline to day 10, 28 and 90.|Pulmonary fibrosis - related morphological features in CT scan at day 90 a. cord-like shadow b. honeycomb-like shadows c. interlobular septal thickening d. intralobular interstitial thickening e. pleural thickening|Lung densitometry: Change in total voxel 'weight' in lesion area voxel 'weight'=voxel density (in HU) × voxel volume (in voxel)|Lung densitometry: volumes histogram of lung density distribution (<-750, -750~-300, -300~50, >50) at day 10, 28 and 90.|Time to clinical improvement in 28 days.|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Blood oxygen saturation|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)|mMRC (Modified Medical Research Council) dyspnea scale|Changes of absolute lymphocyte counts and subsets from baseline to day 6, 10, 28 and 90.|Changes of cytokine/chemokine levels from baseline to day 6, 10, 28 and 90.|Adverse events|Serious adverse events|All-cause mortality",1,100
608,All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation,1,100
609,Change in patient's skin condition|Evaluation of skin problems. Assessment of skin related complaints since the last visit.|The assessment of the scar by the patient.|Changes in volume of the skin (USG)|Changes in skin surface morphology (digital imagining)|Record of adverse events,1,100
610,"To determine the overall safety of MPCs plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).|To evaluate the change of treated lumbar intervertebral discs using Magnetic Resonance Imaging (MRI) at 6 months post injection of MPCs.|To evaluate the effectiveness of MPCs in reducing chronic lumbar back pain using the visual analog scale (VAS).",1,100
611,VAS score|WOMAC score|IKDC score|KOOS score|PROMIS29 score|Kellegren-Lawrence grading|Interleukins,1,100
612,Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.|Arm 2. Efficacy of MSC infusion as treatment for poor graft function|Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT|Toxicity of MSC infusion,1,100
613,Number of study participants with treatment related adverse events (TEAES) and serious adverse events (SAEs) from baseline through Week 104.|Visual Analogue Scale for Pain Assessment - Changes from Baseline in pain as assessed with the VAS score through Week 52|Oswestry Disability Index for Functional Assessment -- Changes from Baseline in function as assessed with the Oswestry Disability Index through Week 52.,1,99
614,Engraftment and Time to Engraftment,1,98
615,Duration of clinical benefit (Crohn's disease activity index)|Re-induction of clinical benefit (Crohn's disease activity index)|Improvement in quality of life (Inflammatory Bowel Disease Questionnaire [IBDQ] instrument),1,98
616,Progression free survival (PFS)|Overall survival (OS),1,94
617,Muscle regenerative capacities|Satellite cell dysfunction after sepsis|Regenerative capacities of Human satellite cells in presence of mesenchymal stem cells,1,93
618,over 50% reduction ratio of Eczema Area and Severity Index (EASI) as contrasted with baseline value (EASI-50)|Score change from Baseline in Eczema Area and Severity Index(EASI) score|Percentage of subjects who have EASI-75 (improvement of ≥75% in EASI score from Baseline)|Percentage of subjects who have EASI-90 (improvement of ≥90% in EASI score from Baseline)|Percentage of subjects who have the Investigator's Global Assessment (IGA) score of 0 or 1|Percentage of subjects whose Investigator Global Assessment (IGA) score is decreased by 2 points or more|Score change from Baseline on Pruritus Numerical Rating Scale (NRS)|Percentage of subjects whose Pruritus Numerical Rating Scale (NRS) is improved by 3 points or more|Percentage change from Baseline in Body Surface Area (BSA) affected by Atopic Dermatitis (AD)|Score change from Baseline in the SCORing Atopic Dermatitis (SCORAD) index|Score change from Baseline in the Dermatology Life Quality Index (DLQI)|Score change from Baseline the Patient-Oriented Eczema Measure (POEM)|Change from Baseline in biomarker (Immunoglobulin E [IgE])|Change from Baseline in biomarker (eosinophil count)|Change from Baseline in biomarker (interleukin [IL]-13)|Change from Baseline in biomarker (interleukin [IL]-17)|Change from Baseline in biomarker (thymus and activation-regulated chemokine [TARC])|Change from Baseline in biomarker (interleukin [IL]-22),1,92
619,Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study,1,91
620,Degree of improvement in knee assessments compared to the active control (microfracture)|Number of subjects with adverse events,1,103
621,ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores,1,104
622,Reduction of infarct size|Infarct size reduction|Myocardial perfusion improvement|Increase of left ventricle ejection fraction (LVEF)|Left ventricle ejection fraction (LVEF) change against baseline.|Left ventricle end-systolic volume (ESV) change against baseline.|Left ventricle end-diastolic volume (EDV) change against baseline.|The occurrence of major adverse cardiovascular events|Quality of life improvement,1,105
623,adverse events|the National Institutes of Health Stroke Scale (NIHSS) of 3 months|the Barthel index (BI) of 3 months,1,120
624,Evaluation of best corrected visual acuity change|Evaluation of visual field change|Evaluation of multifocal ERG changes|Evaluation of ERG changes|Evaluation of optical coherence tomography changes|Evaluation of optical coherence tomography angiography changes,1,135
625,Rate of complete remission|Overall survival|Rate of partial remission|Infusion toxicity,1,130
626,Change of Follicle-stimulating hormone (FSH) hormone level|Change of Estradiol (E2) hormone level|Change in Quality of life using Female Sexual Function Index - FSFI questionaires|Change in Quality of life using The Utian Quality of life Scale|The safety of AD MSC therapy in the treatment of sexual function impairment in female,1,130
627,Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality,1,129
628,Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Scar Size Percent (DEMRI)|Change From Baseline in Scar Tissue Mass (DEMRI)|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Scar Size Percent (DEMRI)-Trajectory|Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Participants With Major Adverse Cardiac Events (MACE)|Participants Experiencing Other Significant Clinical Events|Cumulative Days Alive and Out of Hospital for Heart Failure,1,125
629,Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).,1,120
630,Number of participants with uterine niche|Change of uterine scar thickness|Change of uterine scar area|Number of participants with endometritis|Number of participants with wound infection|Immunoglobulin concentrations in breast milk and serum|Adverse events occurrence,1,120
631,Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse,1,120
632,Salivary gland function|Incidence of treatment-emergent adverse events|Patient-Reported Outcome of xerostomia|Salivary composition,1,120
633,7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio|Time to Recovery|Incidence of Serious Adverse Events (SAE)|Number of Patients with All-cause Mortality,1,120
634,the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria|BASDAI score comparing to baseline|BASFI score comparing to baseline,1,120
635,Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs),1,106
636,Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events,1,120
637,Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 3 months|Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 6 months|Change from Baseline Western Ontario McMaster University Osteoarthritis Index (WOMAC) at 12 months|Change from Baseline Visual Analog Score (VAS) at 3 months|Change from Baseline Visual Analog Score (VAS) at 6 months|Change from Baseline Visual Analog Score (VAS) at 12 months|Magnetic Resonance Imaging (MRI) Evaluation|Change from baseline measure of Fall Risk Functional Testing at 3 months|Change from baseline measure of Fall Risk Functional Testing at 6 months|Change from baseline measure of Fall Risk Functional Testing at 12 months|Change from baseline measure of Frailty Functional Testing at 3 months|Change from baseline measure of Frailty Functional Testing at 6 months|Change from baseline measure of Frailty Functional Testing at 12 months|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 3 months.|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 6 months.|Change from baseline measure of Joint Specific Range of Motion Functional Testing at 12 months.|Change from baseline measure of Obesity Functional Testing at 3 months|Change from baseline measure of Obesity Functional Testing at 6 months|Change from baseline measure of Obesity Functional Testing at 12 months,1,120
638,EASI-50|EASI-75|EASI score|SCORAD-50|SCORAD-75|SCORAD score|SCORAD subgroup|Severity|IGA grade|IGA -1 or more grade|IGA -2 or more grade|Total IgE|PGE2 and ECP|Immune cytokine|Remedy used days and frequency|Remedy used subjects,1,118
639,Left ventricle ejection fraction (LVEF) increase|An increase the result of 6 minute walk test|Myocardial perfusion improvement|An improvement the result of spiroergometric test|Left ventricle ejection fraction (LVEF) change against baseline|Left ventricle end-systolic volume (ESV) change against baseline|Left ventricle end-diastolic volume (EDV) change against baseline|NT pro-BNP level|The occurrence of major adverse cardiovascular events|Quality of life improvement,1,115
640,"Joint rank scores (CAFS, Combined Assessment of Functional and Survival)|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score|Time to event",1,115
641,Healing time|Safety: All types of adverse events will be collected|Incidence of relapse|Pain assessed using the Visual Analogue Scale (VAS) for pain|Total time of hospitalization|Total time of immobility|Quality of Life using the Short Form 36 (SF-36) questionnaire,1,112
642,Ranges of Movement of ankle joint|duration of hospital stay|Weight bearing capacity of patients,1,110
643,WOMAC Score|MRI quantitative analysis of articular cartilage|VAS Score|SF-36|Adverse Events and Serious Adverse Events|Changes of laboratory test indexes and vital signs,1,108
644,overall cure rate|time to cure,1,107
645,"Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2).",1,106
646,"Number of Adverse Events and Severe Adverse Events|Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)",1,53
647,Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation,1,52
648,Number of patients with fistula healed|Number of adversus events,1,52
649,Safety of administration of adipose tissue-derived mesenchymal stem cells measured as reported adverse events|Safety of administration of adipose tissue-derived mesenchymal stem cells measured as neurological o systemic complications|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the Modified Rankin Scale|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the NIHSS|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measuring blood brain repair biomarkers,1,30
650,Mortality|Length of stay in the hospital,1,30
651,"A reduction in the distance in mm from the bottom of the periodontal pocket to the cementoenamel junction using a manual probe (Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) with 20-25g of pressure by a single calibrated examiner.|A reduction in the distance in mm between the gingival margin and the bottom of the defect using a manual periodontal probe (Hu-Friedy XP-23/QW) by a single calibrated examiner.",1,30
652,"Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters.|Percentage of area change of study ulcer from baseline to weeks 12 and 24|Number of days to complete ulcer healing|Number of days to 50% ulcer healing|Percentage change in ulcer volume from baseline to weeks 12 and 24|Changes from baseline in ulcer pain assessed using a Numeric Rating Scale|Number clinic/home care visits across groups|Differences across groups on ulcer dressing products used|Changes from baseline in Quality of Life assessed using the Cardiff Wound Impact Schedule|Duration of clinic/home care visits across groups",1,30
653,Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers,1,30
654,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)",1,30
655,Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL,1,30
656,Safety and tolerability,1,30
657,"Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment",1,30
658,Evaluation of Knee Functions|Evaluation of Physical Activity|Evaluation of Pain|Evaluation of Radiological Images|Evaluation of Cytokine Levels and Cytokine Genes Analyzes|Evaluation of Edema|Evaluation of Knee Joint Range of Motion|Monitoring of treatment-related complications,1,30
659,Changes in pain intensity|Changes in Physical functioning of knee joints.|Changes in femoral cartilage thickness,1,30
660,Skin aging changes evaluated by dermoscopy photoaging scale (DPAS)|Skin aging changes evaluated by Janus-3Ⓡ skin analyzer|Skin capacitance evaluated by the CorneometerⓇ|Transepidermal water loss evaluated by the TewameterⓇ|Likert scale for the satisfaction degree|Visual analog scale (VAS) of pain for the convenience degree|Number of adverse events experienced during the clinical trial,1,30
661,Efficacy|VAS pain score|Improvement rate of VAS pain score|Modified Mayo Clinic Performance Index|Ultrasonic photography|Safety,1,30
662,Insulin dose|Adverse events|Hemoglobin A1c (HbA1c) level,1,30
663,WOMAC pain score|MRI|Visual Analogue Scale (VAS)|12-item Short Form (SF-12),1,30
664,Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers,1,30
665,The changes in HbA1C level|Reduction of insulin requirement|The changes in blood glucose level,1,30
666,The primary objective of the study is to assess the safety and tolerability of MPC therapy|Exploratory assessment of the efficacy of MPC therapy,1,30
667,Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation,1,30
668,Day-100 incidence of non-relapse mortality|1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution,1,30
669,"Expression of PARP1 gene as indicator of base excision repair|Expression of genes ATM, RAD51, RAD52 and WRN as indicator of Recombinational repair|Expression of genes RAD23B and ERCC1 as indicator of Nucleotide excision repair|Expression of genes MLH1, MSH2 and MSH6as indicator of Mismatch repair",1,30
670,"To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells|To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.",1,30
671,• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP),1,30
672,Adverse Events|Kidney Function,1,30
673,Number of Participants with abnormal Total bilirubin|Number of Participants with abnormal albumin|Ishak Inflammation Rating System|Ishak Fibrosis Score|Overall survival (OS)|HBV-DNA|incidence of liver cancer|Number of Participants with abnormal immunoglobulin|portal vein flow rate|portal vein width|abdominal volume|Number of Participants with abnormal coagulation function,1,30
674,"Change in SARS-CoV-2 log viral load from baseline to Day=7|Change in viral load area under the curve (AUC) from baseline to Day=29|Proportion of patients showing symptom improvement or resolution Day=7, 11, 15|- Proportion of patients who required COVID-19 related hospitalization or Emergency Department Visit by Day 29",1,30
675,"Number of adverse serious unexpected reactions or not, attributable to the treatment (SUSSARs or SAE)|Complications in the place of the infusion|Appearance of a new neurological effect not attributable to the natural progression of this pathology|Changes in the progression of the disease (modifications in the scale of functionality of the ALS)|Changes in the degree of muscular force|Changes in the vital forced capacity|Changes of the muscular mass estimated by Nuclear Magnetic Resonance (NMR) of the upper and low extremities|Changes in neurophysiological parameters and of quality of life|Need and time to tracheotomy or permanent assisted ventilation",1,52
676,improvement in Visual Analogue Scale|improvement in Oswestry Disability Index|Change in the T score (lumbar spine and femoral neck) of dual-energy x-ray absorptiometry|Presence of new vertebral fracture|Change in the bone mineral density (computed tomography) of fractured vertebrae,1,30
677,Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Epithelialization|Assessment of further wound healing parameters: formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs at Week 6.1 and Week 12,1,31
678,Safety|Efficacy,1,31
679,Improvement in myocardial perfusion measured by SPECT|Safety|Improvement in myocardial perfusion and function measured by PET and MR|Exercise time|Clinical angina status,1,31
680,feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study,1,31
681,Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI,1,30
682,Change of pain visual analogue scale (VAS) during activity|Change of pain visual analogue scale (VAS) at rest|Change of Mayo elbow performance index (MEPI)|Ultrasonographic assessment|Shear wave elastography|Magnetic resonance image (MRI) assessment,1,30
683,Number of Participants with Adverse Events as a Measure of Safety|Change in whole saliva production|Subjective complaints of xerostomia|Change in volume and vascularisation - MRI of glands - composite|MRI - Change in fibrosis|histological sections - gland tissue - composite|histological sections - fibrosus|histological sections - vascularisation,1,30
684,To assess the safety of Descartes-30 in patients with moderate-to-severe ARDS.,1,30
685,"Change of the Constant-Murley score|Change of the VAS pain score|Change of range of motion (ROM)|clinical change based on the DASH scale (disability of the arm, shoulder and Hand)|clinical change based on the , American Shoulder and Elbow Surgeons (ASES) score|evaluation of shoulder MRI results|evaluation of shoulder X-ray (XR) results",1,30
686,Liver function test|MELD score|Cirrhosis mortality after 6 months,1,30
687,Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive,1,30
688,Change in proportion of senescent cells (representing the total senescent cell burden) present|Change in proportion of senescent mesenchymal stem cells present|Change in mesenchymal stem cell function|Change in Frailty index score|Change in kidney function,1,30
689,Bone formation on interface between bone tunnel and graft|Arthroscopic grading of graft|Telos stress X-ray|KT-2000|clinical knee scoring|Instability assessing with physical examination|Tunnel enlargement after anterior cruciate ligament reconstruction,1,30
690,Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function,1,30
691,"The patient is alive, the patient has not undergone any major amputation, complete primary wound healing has been achieved, no ipsilateral relapse has occurred|Rate major amputations Rate of patients with complete ulcer healing Rate of treatment related complications Improvement of ankle brachial index (ABI) Improvement of transcutaneous oxygen partial pressure (TcPO2) Improvement of local perfusion",1,30
692,"All-cause mortality at day 28|Safety of WJ-MSC|Need for treatment with rescue medication|Need and duration of mechanical ventilation|Ventilator free days|Evolution of PaO2 / FiO2 ratio|Evolution of the SOFA index|Evolution of the APACHE II score|Duration of hospitalization|Evolution of markers of immune response (leucocyte count, neutrophils)|Feasibility of WJ-MSC administration|Evolution of disease biomarker: polymerase chain reaction (RT-PCR)|Evolution of disease biomarker: lactate dehydrogenase (LDH)|Evolution of disease biomarker: D-dimer|Evolution of disease biomarker: Ferritin",1,30
693,The glucose concentration in blood|The glycated hemoglobin concentration|The C-peptide level in blood|Autoantigen specific T cell count|Adverse effects associated with the therapy,1,30
694,"PaO2 / FiO2 ratio|respiratory function evolution|respiratory assistance|organ failures 1|organ failures 2|organ failures 3|duration of intensive care|Cause of death|respiratory morbidity (TDM, functional respiratory measures)|viral load|Anti-HLA antibody rate|immediate hypersensitivity reactions|thromboembolic adverse events 1|thromboembolic adverse events 2|infectious adverse events",1,30
695,Decrease in joint pain|Increased joint functionality|Improvement in the quality of life|Imaging improvement of articular cartilage,1,30
696,PaO2/FiO2|the days of ventialtion and hospital stay,1,30
697,Change in inflammatory markers including C-reactive protein|Effect on Mesenchymal stem cell function including cell migration|Effect on measures of Frailty including Fried Criteria|Kidney function including estimated glomerular filtration rate|Kidney function including urine protein excretion rate|Number of participants with treatment-related adverse events including hospitalization,1,30
698,Albumin (ALB)|Alanine aminotransferase (ALT)|Prealbumin (PA)|Total bilirubin (TB)|Direct bilirubin (DB)|Blood urea nitrogen (BUN)|Uric acid (UA)|Serum creatinine (Scr)|Child-Pugh|Model for end-stage liver disease (MELD)|Quality of life (QOL),1,30
699,"Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months.",1,30
700,Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Visual Analogue Scale (VAS)|Harris Hip Scale (HHS),1,30
701,"Global Gene expression profile of bone marrow-derived mesenchymal stromal cells from osteoarthritic versus healthy donors|Flow cytometric analysis of cell surface antigens, Alkaline phosphatase activity, DNA content as measure for cellular proliferation",1,30
702,Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR|Post-PCI coronary artery endothelial function as assessed via FFR|Target lesion lumen loss|Flow Mediated Diameter Percentage (FMD%)|EPC-CFUs levels|Circulating angiogenic factors marker levels|Circulating inflammatory markers|Seattle Angina Questionnaire (SAQ) Angina Frequency|EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire|EQ-5D Quality of life Questionnaire Overall Health Status Question|Short Form (SF) 36 Questionnaire Quality of Life Questionnaire|International Index of Erectile Function (IIEF) Questionnaire|Sexual Quality of Life - Females (SQOL-F) Questionnaire|Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)|Incidence of Major Adverse Cardiac Events (MACE)|Rates of Adverse Events|Number of participants with abnormal lab values|Number of participants with Target Vessel Failure,1,30
703,"Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events.|Number of fractures.|Time (days) to first fracture after each stem cell administration.|Numbers of fractures at birth.|Change in bone-marrow density (g/cm2).|Growth (cm).|Growth (kg).|Change in clinical status of OI.|Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples.",1,30
704,Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC),1,26
705,MRI scan|WOMAC score|WOMAC sub-scale|Kellgren & Lawrence grade|EQ5D|ROM|KOOS (Knee Injury & Osteoarthritis Outcome Score)|PGIC(Patient Global Impression of Change)|PSQI(Pittsburgh Sleep Quality Index)|Biomarkers|Incidence of adverse reactions and characteristics associated with investigational product,1,26
706,"Nature, incidence and severity of adverse events (AEs)",1,25
707,Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT,1,25
708,Collection of adverse events|Safety laboratory values|ECG findings|Analysis of inflammation markers|Comparison of course of haemodynamic and vascular processes,1,25
709,Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire),1,25
710,Number of Participants With Adverse Reaction (AE) and Severe Adverse Reaction (SAE),1,24
711,"Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Pain pre-surgery|Pain at follow-up 12 months|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months|Constant-Murley Score (CS) pre-surgery|Constant-Murley Score (CS) at follow-up 12 months|Tear recurrence (re-tear)",1,24
712,WOMAC score|WOMAC 3 subscale|KOOS (Knee Injury & Osteoarthritis Outcome Score)|SF(Short Form)-36 Score|Global assessment of disease activity|Overall satisfaction|X-ray|MRI scan|Arthroscopy evaluation|Histological evaluation|VAS|IKDC|ROM|Quadriceps power|effusion|Crepitus|Ligament laxity|Medial joint line tenderness|Pes tenderness,1,24
713,Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality,1,24
714,Safety|Number of patients reaching clinical union of fracture,1,24
715,"Change of Pain During Activity From Baseline to 3 Months After Intervention|Pain During Rest|Pain During Activity|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|Disability of Arm, Shoulder and Hand (DASH) Score|University of California, Los Angeles(UCLA) Shoulder Score|Tear Size at 3 Months After Injection|Tear Size at 12 Months After Injection",1,24
716,Treatment related adverse events|Complete clinical healing|Clinical response|Partial clinical response|Lack of response|Crohn's disease activity index|Inflammatory bowel disease questionnaire|EuroQol 5 Dimensions survey|Inflammatory bowel disease patient reported treatment impact survey|Short Form 36 health survey,1,24
717,Irregular menstruation patients efficacy evaluation|Intrauterine adhesion patients efficacy evaluation,1,24
718,"Validation of the cell-free approach based on the use of ASC secretome on an ex vivo OA model by evaluation of cell viability, histological features and gene/protein expression of cartilage and bone biomarkers",1,24
719,Serum albumin in g/L|alanine aminotransferase in U/L|aspartate aminotransferase in U/L|cholinesterase in U/L|Total bilirubin in μmol/L|Direct bilirubin in μmol/L|Serum cholesterol in mmol/L|Prothrombin activity in percentage|Antithrombin in mg/L|survival rate|Child-Pugh grade|Rate of weight change|Ascites|clinical symptoms|Th1 cells in percentage|Th2 cells in percentage|Natural killer T cells in percentage|Interleukin-1β cells in pg/mL|Interleukin-4 cells in pg/mL|Interleukin-6 cells in pg/mL|Interleukin-8 cells in pg/mL|Interleukin-12 cells in pg/mL|Interleukin-15 cells in pg/mL|Interleukin-17A cells in pg/mL|Medical images|The Medical outcomes study 36-item Short Form Health Survay scale (SF-36 scale)|MELD score,1,24
720,Percentage of Participants who Achieve Combined Remission|Percentage of Participants who Achieve Clinical Remission|Percentage of Participants who Achieve Clinical Response|Percentage of Participants who decrease in PDAI|Percentage of Participants who decrease in IBDQ|Percentage of Participants who decrease in VAS scale|Percentage of Participants who decrease in Wexner incontinence score,1,24
721,Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS,1,24
722,"To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months",1,24
723,Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10,1,24
724,"Changes in MDS-UPDRS Part II.|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities|AEs of special interest (serious or non-serious) - infections|AEs of special interest (serious or non-serious) - hypersensitivities.|Laboratory values. CBC|Laboratory values. CMP|Laboratory values. Coagulation Panel|Vital signs. - Respiratory Rate (breaths per minute)|Vital signs. - Heart Rate (beats per minute)|Vital signs. - Body Temperature (Fahrenheit )|Vital signs. - Blood Pressure (mmHg)|Weight in lb.|Physical examination results. General|Physical examination results. Body Systems.|Changes in MDS-UPDS total score.|Changes in MDS-UPDRS Part I.|Changes in MDS-UPDRS Part III.|Changes in MDS-UPDRS Part IV.|Changes in Neuro-QOL. - Communication|Changes in Neuro-QOL. - Social Roles and Activities|Changes in Neuro-QOL. - Anxiety|Changes in Neuro-QOL. - Depression|Changes in Neuro-QOL. - Dyscontrol|Changes in Neuro-QOL. - Fatigue|Changes in Neuro-QOL. - Mobility|Changes in Neuro-QOL. - Well-Being|Changes in Neuro-QOL. - Sleep|Changes in Neuro-QOL. - Fine Motor|Changes in Neuro-QOL. - Stigma|Changes in Neuro-QOL. - Social Roles|Changes in Neuro-QOL. - Cognition|Changes in Parkinson's disease fatigue scale (PFS-16).|Changes in Parkinson's disease Questionnaire (PDQ-39).|Changes in Visual Analog Scale for Pain.|Changes in Dosage of medications taken to treat Parkinson's disease.|Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).|Incidence and risk of AEs of special interest (serious or non-serious),|Clinically significant changes in laboratory values. - CBC|Changes in Visual Analog Scale for muscle spasms.|Clinically significant changes in vital signs. - Respiratory Rate|Clinically significant changes in vital signs. - Heart Rate|Clinically significant changes in vital signs. - Body Temperature.|Clinically significant changes in vital signs. - Blood Pressure.|Clinically significant changes in vital signs. - Oxygen Saturation.|Clinically significant changes in physical examination results.|Clinically significant changes in weight in lb.|Clinically significant changes in laboratory values. - CMP|Clinically significant changes in laboratory values. - Coagulation Panel",1,24
725,"Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)|Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment",1,24
726,MR Elastography|The level of serum alanine aminotransferase (ALT)|Clinical Examination|The level of glomerular filtration rate (GFR)|The level of serum albumin (ALB)|The level of serum total bilirubin (TB),1,700
727,live birth rate|Reduction of intrauterine adhesion|The change of endometrial thickness|ongoing pregnant rate,1,26
728,Complication rate|complication rate|Progression of disease to the next stage|Amount of necrotic bone in the femoral head in MRI|Pain (VAS)|serum levels of bone turnover markers,1,26
729,Numeric Pain Rating Scale (NPRS)|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|Goniometer (range of motion)|SF-12 (quality of life),1,26
730,"Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group|Change From Baseline on Visual Analog Scale (VAS) in JointStem Group|MRI Improvement Evaluation in JointStem Group|Change From Baseline on WOMAC Between JointStem and Positive Control Groups|Change From Baseline on VAS Between JointStem and Positive Control Groups|Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups|Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups|Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups|Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups|Change From Baseline on WOMAC in JointStem Group|Change From Baseline on VAS in JointStem Group|Comparison of MRI Improvement Evaluation in JointStem Group|Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12|Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group",1,28
731,Baseline Visual analogue scale (VAS)|Baseline value of knee injury and osteoarthritis outcome score (Koos).|Baseline Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC).|Baseline SF-36 value|Baseline euroquol 5D value|Baseline Lequesne index|Baseline femorotibial distance|Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events Number of Participants with Serious and Non-Serious Adverse Events|Visual analogue scale (VAS) at on month|Visual analogue scale (VAS) at 3 months|Visual analogue scale (VAS) at 6 months|Visual analogue scale (VAS) at 12 months|Value of knee injury and osteoarthritis outcome score (Koos) at 1 month|Value of knee injury and osteoarthritis outcome score (Koos) at 3 month|Value of knee injury and osteoarthritis outcome score (Koos) at 6 month|Value of knee injury and osteoarthritis outcome score (Koos) at 12 months|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 1 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 3 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 6 month|Western Ontario and McMaster Universities Osteoarthritis Index score (WOMAC) at 12 months|SF-36 value at 1 month|SF 36 value at 3 months|SF 36 value at 6 months|SF 36 value at 12 months|Euroquol 5D value at 1 month|Euroquol 5D value at 3 months|Euroquol 5D value at 6 months|Euroquol 5D value at 12 months|Lequesne index at 1 month|Lequesne index at 3 months|Lequesne index at 6 months|Lequesne index at 12 months|Femorotibial distance at 6 months|Femorotibial distance at 12 months|Baseline MRI WORMS protocol|MRI WORMS protocol score at 6 months|MRI WORMS protocol score at 12 months,1,30
732,Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Hospital for special surgery knee score postoperative 12 month|Hospital for special surgery knee score postoperative 24 month|Hospital for special surgery knee score postoperative 36 month|Visual Analogue Scale Postoperative Day 1|Visual Analogue Scale Postoperative Day 2|Visual Analogue Scale Postoperative Day 3|Visual Analogue Scale Postoperative Day 7|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Visual Analogue Scale Postoperative 12 month|Visual Analogue Scale Postoperative Day One|Visual Analogue Scale Postoperative 24 month|Visual Analogue Scale Postoperative 36 month|Evaluation of cartilage repair under MRI postoperative 12 month|Evaluation of cartilage repair under MRI postoperative 24 month|Evaluation of cartilage repair under MRI postoperative 36 month|Degree of meniscus injury under MRI postoperative 12 month|Degree of meniscus injury under MRI postoperative 24 month|Degree of meniscus injury under MRI postoperative 36 month|Evaluation of cartilage repair under arthroscope postoperative 12 month|Degree of meniscus injury under arthroscope postoperative 12 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Squatting to Standing Time postoperative 12 month|Squatting to Standing Time postoperative 24 month|Squatting to Standing Time postoperative 36 month,1,30
733,Safety of HUC-MSCs infusion|Difference in rate of decline of Frailty|Difference in subject quality of life assessments|Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts|Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts,1,30
734,Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB),1,30
735,"Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo.",1,30
736,Clinical improvement|Lung damage improvement|Sars-Cov-2 viral infection laboratory test|Blood test,1,30
737,Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10,1,29
738,Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI,1,28
739,Temperature|Pulse|Breaths per minute|Blood pressure|Number of antral follicle|Follicle-stimulating hormone (FSH) serum level|Estradiol (E2) serum level|Anti-Mullerian hormone (AMH) serum level|Ovarian volume,1,28
740,Maximum Tolerated Dose Determined by Dose Limiting Toxicity|Minimal residual disease rate in high-risk patients|Overall survival (OS)|Progression-free survival (PFS),1,28
741,Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF),1,27
742,Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate,1,26
743,Improvement of left ventricular function|Functional status,1,27
744,Investigation of cell proliferation of AT-MSCs|Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte|Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast|Measurement of gene expression profile of AT-MSCs|Healing of anal fistula after treatment|Evaluation of fistula healing after treatment|Functional gastroenterological outcome after treatment|Defecation disorder evaluation after treatment|Functional urological outcome after treatment,1,27
745,Safety profile of ADR-001 including the incidence of adverse events (Phase 1)|Improvement rate of Child-Pugh score (Phase 2)|Change of liver function evaluated by Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh score (Phase 1)|Improvement rate of Child-Pugh grade (Phase 1)|Change of liver function evaluated by Child-Pugh score (Phase 2)|Improvement rate of Child-Pugh grade (Phase 2)|Safety profile of ADR-001 including the incidence of adverse events (Phase 2),1,27
746,Scores on unified MSA rating scale,1,27
747,Changes in Ocular Surface Disease Index (OSDI) Score|Changes in tear secretion amount by Schirmer's Test|Changes in Tear break time|Changes in Ocular Surface Staining|Changes in best corrected visual acuity (BCVA).|Changes in conjunctiva redness score|Changes in tear meniscus height,1,27
748,Viability and safety of mesenchymal stem cell transplant|Absence of complications in pre and peri surgical implantation|Improvement of 2 lines in Best Corrected Visual Acuity,1,27
749,change in number of acute surgeries|change in days of acute inpatient treatment|change in number of curative surgical procedures after oral mucosa transplantation|change in conjunctival inflammation,1,27
750,Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image|Differences the results obtained in the two groups of patients due to determined parameters.,1,26
751,"Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection|Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040|Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040|Mechanical ventilation-free days 28 days after the administration of HCR040|Percent mortality 28 days after the administration of HCR040|Daily pulmonary mechanics values (Ppl, DP, CRS)|Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040|Vasopressor-free days 28 days after the administration of HCR040|ICU-free days 28 days after the administration of HCR040",1,26
752,Safety: Incidence of adverse events improvement) in one or more areas of ailments related to PTHS|Safety: Incidence of serious adverse events|Change in motor function in individuals with PTHS|Change in communication abilities in individuals with PTHS.|Change in sleep habits|Change in gastrointestinal health|Change in breath holding spells|Change in cognition|Change in adaptive function|Change in autistic features|Change in parent assessment of quality of life|Change in global clinical status,1,26
753,"Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months",1,31
754,"Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I|Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II|Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II|Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II|Change from baseline to all post-treatment visits in body weight|Change from baseline to all post-treatment visits in Blood-pressure|Change from baseline to all post-treatment visits in S.creatinine|Change from baseline to all post-treatment visits in blood urea.|Change from baseline to all post-treatment visits in Hemoglobin level|Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)|Change from baseline to all post-treatment visits in hemoglobin A1c|Change from baseline to all post-treatment visits in random blood sugar (RBS)|Change from baseline to all post-treatment visits in Anti-Hypertensive medication if there is any.|Change from baseline to all post-treatment visits in Hypoglycemic agent if there is any.|Change from baseline to post-treatment visits in urine total protein-creatinine ratio (UPCR)|Change from baseline to all post-treatment visits in urinary Protein-to-creatinine ratio PCR)|Change from baseline to post-treatment level of serum Alpha Feto Protein|Change from baseline to post-treatment level of serum CEA level|Change from baseline to post-treatment level of serum CA 19.9 level|Change from baseline to post-treatment level LDH level|Change from baseline to post-treatment level of Beta 2 Microglobulin level|Change from baseline to post-treatment level of serum CA 125 level (in case of female patients)|Change from baseline to post-treatment level of PSA level (in case of male patients)",1,31
755,Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Measure patients Quality of Life using a questionnaire|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Number of participants experiencing Acute GVHD,1,32
756,Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group,1,40
757,Bone consolidation|Radiological Bone consolidation|Level of Pain|Complications|Health status,1,46
758,Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure,1,46
759,Number of subjects with adverse events|Change from the baseline in ADAS-Cog|Change from the baseline in S-IADL|Change from the baseline in K-MMSE|Change from the baseline in CGA-NPI|ADAS-Cog Response Rate|Change in CDR-SOB|Change in Florbetaben-PET|Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)|Change in CIBIC-plus|Change from baseline in MRI (DTI mapping)|Change from the baseline in CSF biomarkers,1,46
760,Assessment of endometrial receptivity|Clinical pregnancy rate|Treatment-Emergent Adverse Events,1,46
761,Changes in wound size|Changes in wound morphology|Changes in pro-angiogenic factors expression|Changes in wound-associated pain|Changes in the quality of life|Record of adverse events,1,46
762,Determination of recommended Phase II dose (RP2D) of MSCTRAIL in combination of cisplatin and pemetrexed treatment (Phase 1)|Tumour response rate (Phase 2)|Frequency of adverse events (Phase 1 & 2)|Best Overall response (Phase 1&2)|Progression free survival (Phase 1 & 2)|Overall survival (Phase 2),1,46
763,Incidence of AEs|Mortality|Death|Number of ventilator-free days|Improvement of one category|7-point ordinal scale|NEWS|NEWS of ≤ 2|Sequential Organ Failure Assessment (SOFA)|Oxygen|Hospitalization|Incidence of SAEs,1,45
764,Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation,1,45
765,"Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale|Safety and tolerability as measured by serious adverse reactions.|Safety and tolerability as measured by immunologic responses.|Motor function as measured by the Timed-Up-and-Go (TUG) scale|Global measurement of disability as measured by the change in the screening ""Off"" modified Hoehn and Yahr (H&Y)|Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)|Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)|Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)|Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).|Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)|Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)|Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)|Measurement of putative paracrine mechanism of MSCs using neuroimaging|Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors|Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid",1,45
766,Scale for the assessment anf rating of ataxia (SARA)|Image examinations|Inventory of Non-Ataxia Symptoms (INAS) score|Cerebrospinal fluid (csf) routine,1,45
767,survival rate|Adverse reactions|White blood cell|Platelet|Hemoglobin|Creatinine|ALT|ALB|TBil|INRs|AFP|MELD scores|Tumor formation|Liver failure-associated serious complications,1,45
768,Adverse events and serious adverse events|Reduced activities|Slowing of mobility|reduction of handgrip strength|exhaustion|the level of pain in the knee|respiratory function|Quality of Life|patients' inflammation|patients' immune|immunoregulatory properties of umbilical cord-derived mesenchymal stem/stromal cells|Cellular senescence|metabolic profiles of CD3+ cells,1,44
769,MRI integrity|American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES)|University at California at Los Angeles Shouder Rating Scale (UCLA)|Visual Analog Scale for Pain (VAS),1,44
770,"Change of GFR|Incidence of Treatment-Serious Adverse Events as assessed by SPSS 23.0 and Graphpad prism 6|Number of participants with treatment-related adverse events as assessed by SPSS 23.0 and Graphpad prism 6|IgA|IgG|IgM|C3|C4|CRP|IL-6|Peripheral hemolymocyte subsets|Urine protein|Urine RBC|24-hour urine protein|Urine albumin/creatinine|Electrolytes|Hemoglobin|Albumin|Heart ultrasound|Carotid ultrasound|NT-proBNP|iPTH+1,25-VitD3",1,44
771,Macular holes closure|Best corrected visual acuity(BCVA),1,44
772,Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro,1,43
773,changes in myocardial metabolic activity|Changes in left ventricular ejection fraction (LVEF)|incidence of cardiovascular events|overall mortality|adverse events at 12 months after transplantation of autologous BM-MSCs,1,43
774,Rate of adverse event|Rate of serious adverse event|Rate of cure rate,1,43
775,Change of TCSS scale|Change of nerve conduction velocities in the lower extremity|Change of serum inflammatory factors|Change of growth factors (GF)|Change of fasting plasma glucose (FPG)|Change of glycosylated hemoglobin (HbA1c),1,42
776,Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score,1,42
777,Duration of hospital stay|Post-administration clinical and radiological improvement|Adverse Event and Serious Adverse Event Evaluation,1,42
778,Change in Kidney function|Safety of Mesenchymal stem cell infusion|Decrease in Kidney inflammation,1,42
779,Primary Endpoint for Phase I portion|Primary Endpoint for Phase IIa portion|Efficacy endpoint for phase I portion|Efficacy endpoints for phase IIa portion|The safety endpoints are listed below for both phase I and IIa portions,1,41
780,"Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage",1,47
781,"Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes|inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality",1,48
782,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,1,48
783,number of adverse events after infusion of MSC (hPPL)|Number of severe infections after MSC infusion|Response of acute GVHD|Determination of incidence of chronic GVHD|Survival,1,50
784,Avoiding arthroplasty|Harris Hip Score,1,52
785,Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration,1,52
786,Changes in Motor Performance.,1,50
787,Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function,1,50
788,endometrial thickness|ongoing pregnancy rate|live birth rate|endometrial blood flow,1,50
789,VAS score|Kellgren-Lawrence score,1,50
790,motor symptoms change|non-motor symptoms change|sleep quality change|daytime sleepiness change|signs of depression change,1,50
791,reduction of total prosthesis|Pain reduction|functional status,1,50
792,Incidence of treatment-emergent adverse events|Myocardial blood flow|Left ventricle ejection fraction (LVEF)|Infarct size|New York Heart Association (NYHA) Functional Classification|Canadian Cardiovascular Society (CCS) Angina Grading Scale,1,50
793,"Change in pain-free walking distance|Amputation-free survival period|Ulcer-free survival|Ulcer-extension free survival|Change in tissue oxygen/CO2 tension|An improvement of tissue perfusion|Change in transcutaneous pressure of O2|Change in ABI score|Quality of life improvement, assessed by SF-36 questionnaire",1,50
794,"The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint|The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration|LV end diastolic volume|LV end systolic volume|Infarct size measured by MRI, with contrast|Global Left Ventricular Ejection Fraction",1,50
795,Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion|Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA|Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA,1,48
796,Evaluation of safety related adverse ocular events including immune response|Ophthalmic examination for best-corrected visual acuity (BCVA) using early treatment of diabetic retinopathy study (ETDRS) chart|Measurement of electrical activity/function of retina using Electroretinography (ERG) test|Evaluation of outer retinal thickness using Optical Coherence Tomography (OCT) imaging test|Examination of retinal damage by Fundus Photography|Evaluation of visual field sensitivity using perimeter,1,50
797,change in cough test & urodynamic study as a measure of efficacy of treatment|Quality of life as measured by the Incontinence Quality of Life (I-QOL) Instrument Score,1,50
798,Recording of Adverse Events and Serious Adverse Events|International Knee Documentation Committee (IKDC) score|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Visual Analog Score (VAS)|Magnetic resonance imaging (MRI)|Immunohistochemistry (IHC),1,50
799,"Safety|Complete and partial resolution of graft-vs-host disease (GVHD)|Cytokine levels, lymphocyte subsets, and donor-reactive lymphocyte numbers in patients with acute GVHD",1,49
800,"Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord|Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC|Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)|Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.|Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test",1,48
801,"Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy",1,48
802,Safety Assessment|Neurological efficacy|EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology,1,48
803,Change in patients clinical manifestation|Need for a ventilator|Duration of using a ventilator|Length of stay|Routine blood profile|CRP|D-dimer|Blood Gas Analisis (BGA)|Photo thorax|Survival,1,48
804,Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay,1,48
805,Adverse events and serious adverse events|National Institutes of Health Stroke Scale (NIHSS) score|Functional Independence Measure (FIM) score|Modified Ashworth Scale|Fine motor skills (FMI) score|Short Form 36 items (SF-36) score,1,48
806,Assessment of inflamation marker levels|Assessment of clinical outcome|Assessment of laboratory routine|Assessment of photo thorax|Assessment of RT-PCR conversion|Mortality rate,1,40
807,Magnetic resonance angiography,1,40
808,"Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)|Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90",1,32
809,physical function improvement|change in pain density|joint swelling|joint erythema|deterioration of joint function|Allergic reactions,1,40
810,Adherence|Recruitment|Modified Physical Performance Test|6-Minute Walk Test,1,36
811,Severity and incidence of adverse events (SIAE) on the 3rd day after the first administration|1 week SIAE after the first administration|3 weeks SIAE after the first administration|3 week SIAE after the the second administration|1 month SIAE after the last administration|3 months SIAE after the last administration|6 months SIAE after the last administration|12 months SIAE after the last administration|24 months SIAE after the last administration|Child-Pugh score (effectiveness evaluation index)|Survival rate (effectiveness evaluation index)|Liver function (effectiveness evaluation index)|The Model for End-Stage Liver Disease (MELD) score (effectiveness evaluation index)|KPS score (effectiveness evaluation index)|Detection of Blood Coagulation Index of PT (effectiveness evaluation index)|Detection of Blood Coagulation Index of APTT (effectiveness evaluation index)|Detection of Blood Coagulation Index of TT (effectiveness evaluation index)|Detection of Blood Coagulation Index of FIB (effectiveness evaluation index),1,36
812,"Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery.",1,36
813,Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies,1,36
814,Number of Participats Showing Efficacy (Functionality)|Change in Pulpal Response|Change in Apical Lesion Size|Pain to Percussion|Numbers of Participants With Adverse Event|Pulp Regeneration,1,36
815,"The change from baseline in modified Marshall score on Day 7 for organ failure subject|The change from baseline in CTSI Score on Day 28|Percentage of subjects whose organ failure was resolved at 3 days, 7 days, 14 days and 28 days|The change from baseline in modified Marshall score at each assessment point up to Day 28|The change from baseline in sequential organ failure assessment (SOFA) at each assessment point up to Day 28|Duration of Systemic inflammatory response syndrome (SIRS)|Time to resolution of organ failure|The change from baseline value of C-Reactive Protein(CRP) which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of Tumor Necrosis Factor(TNF)-α which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-6 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of interleukin(IL)-8 which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|The change from baseline value of lymphocyte count ratio which is inflammatory marker on Day 1, 2, 3, 5, 7, and 14|Duration of intensive care unit (ICU) stay|The change from baseline in Computed Tomography Severity Index(CTSI) on Day 28|Incidence of pancreatic complication|Requirement of drainage or surgery|Rate of infection|Mortality on Day 28 and 90",1,36
816,Proportion of subjects who are completely blocked fistula|Proportion of subjects who are more than 50% blocked fistula|Score of evaluation about Investigator satisfaction using questionnaire|Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test|Visual improvement effect of perianal fistula wound through photography of it,1,36
817,Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity,1,36
818,Change Quality of Life assessed by the Emory Quality of Life (EQOL) Survey Score|Change in the Knee Injury and Osteoarthritis Outcome Score (KOOS)|Capacity of Isolated Cells to Differentiate Down Cell Lineages,1,35
819,Effective Dose|Clinical neurological worsening over the treatment|BMI assessment|Risk of suicidal ideation|CNS assessment|Clinical Interview Based impression of Severity (CIBIS),1,35
820,"Safety: Adverse Events|Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score",1,35
821,Presence of small genetic alteration in mesenchymal stem cells,1,35
822,Maintenance of effectiveness on clinical progression of the disease|Clinical neurological worsening over the treatment by UHDRS|BMI assessment|Risk of suicidal ideation and/or behavior by C-SSRS|Risk of suicidal ideation and/or behavior by HDS|CNS assessment by MRI (Magnetic Ressonance Imaging),1,35
823,Increased expression of chondrogenic markers|Increasing secretion of anti-inflammatory molecules in vitro,1,35
824,post operative liver injury|Total Bilirubin level|(INR) International Normalized Ratio|(ALT) Alanine Aminotransferase|(AST) Aspartate Aminotransferase,1,35
825,"Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)|Major adverse event (death, target limb amputation)|Ankle Brachial Index|University of Texas Classification at target limb",1,33
826,Number of adverse events and serious adverse events|Evolution of chronic critical ischemia,1,33
827,To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease.|Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following.,1,33
828,ETDRS visual acuity|Outer retinal thickness,1,32
829,X-ray evaluation immediately following surgery.|X-ray evaluation at 4 weeks following surgery|X-ray evaluation at 8 weeks following surgery.|X-ray evaluation at 12 weeks following surgery.|X-ray evaluation at 16 weeks following surgery.|Ultrasonography evaluation at 2 weeks|Ultrasonography evaluation at 4 weeks|Ultrasonography evaluation at 8 weeks|Ultrasonography evaluation at 12 weeks|Ultrasonography evaluation at 16 weeks|Functional evaluation at 8 weeks following surgery.|Functional evaluation at 12 weeks following surgery.|Functional evaluation at 16 weeks following surgery.,1,32
830,Overall Survival Rate Through Day 180|Overall Survival Rate at Day 180 for Participants Who Had Overall Response (OR) at Day 28 of Study MSB-GVHD001,1,32
831,Knee Injury and Osteoarthritis Outcome Score|Numeric Pain Rating Scale|Patient Reported Outcome Measurement Information System Global Health Scores,1,32
832,Inflammatory response as measured by laboratory measurements and functional assays of innate immunology,1,32
833,Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire,1,37
834,Childhood Autism Rating Scale，CARS|Clinical Global Impression Scale，CGI|Aberrant Behavior Checklist，ABC|Adverse Event and Serious Adverse Event,1,37
835,The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.,1,38
836,"Safety|Liver function tests.|CT scan of abdomen.|Change in MELD score|Improvement in quality of life as assessed by SF 36 questionnaire|Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA|Change in Child-Pugh score",1,40
837,Patient satisfaction (Patient Assessment Scar Scale)|Doctor satisfaction (Vancouver Scar Scale),1,40
838,Cytokine profile in supernatants|Immune phenotyping|Genetic predisposition to hyperinflammation,1,40
839,Safety measured as the number of Major Adverse Cardiac Events (MACE)|Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up,1,40
840,Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council,1,40
841,Ocular Surface Disease Index (OSDI)|Non-invasive keratography tear break-up time (NIKBUT)|Tear meniscus height (TMH)|Schirmer's I test|Tear osmolarity|Oxford scale|HLA anti-bodies,1,40
842,Safety of aMBMC administration|Efficacy of aMBMC administration,1,40
843,Left ventricular ejection fraction|Mortality|NT-proBNP|Left ventricular end diastolic diameter|6 minutes walking distance|Minnesota Living with Heart Failure Questionnaire（MLHFQ）|PET/CMR,1,40
844,•Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|change in Neurogenic Bladder Symptom Score (NBSS)|change in Neurogenic Bowel Symptom Score|Incidence of abnormal CSF composition|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Correlation of adverse events to study drug,1,40
845,Survival Rates|Contraction Rates,1,40
846,Treatment related adverse events|Complete clinical healing,1,40
847,Endothelial function: Changes in endothelial function as assessed by the following:|Difference in rate of change in the metabolic syndrome as defined by the following:,1,40
848,Achievement of Global Renal Response (GR) at Study Endpoint|Achievement of Complete Renal Response (CR) at Study Endpoint|Achievement of Partial Renal Response (PR) at Study Endpoint|Treatment Failure|Response of SLE Responder Index (SRI).|Selena Sledai|BILAG score|Disease Flares|Biomarker Response,1,39
849,Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0,1,40
850,Tissue and Hematopoietic Stem Cell Collection|Identify pharmacodynamic markers,1,40
851,Crohn's disease activity index score|simplified endoscopic score for Crohn's disease|Inflammatory Bowel Disease Questionnaire|Albumin|Hemoglobin|Fecal calprotectin|body mass index (BMI),1,40
852,"Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between ""Sequential Organ Failure Assessment"" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.",1,40
853,"Infusional toxicity|Incidence of infections (bacterial, viral, fungal, parasitic) and cancers|Patient and graft survivals|Effects of MSC on graft function|Biopsy-proven (Banff classification) rejection rates|Feasibility and safety of weaning or decreasing immunosuppression|Recipient's immune function|Anti-MSC donor HLA antibodies.",1,40
854,Adverse events and/or serious adverse events,1,40
855,Synovial Fluid Cytokine Measurement,1,40
856,lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9),1,40
857,CD34+ Endothelial Progenitor Cell number|CD34+ Endothelial Progenitor Cell Migration against serum SDF1a gradient|Gene Expression of CD34+ Endothelial Progenitor Cell number|Gene Expression of Subcutaneous Adipose cell|Arterial Stiffness: Pulse Wave Velocity|Arterial Stiffness: Pulse Wave Analysis|Body Composition: BMI|Body Composition: Body Fat Percent|Hip to Waist Ratio|Biochemistry: HbA1c|Biochemistry: LDL over HDl Ratio,1,40
858,Incidence of infusion-related adverse events|Incidence of any treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)|Selection of an appropriate dose of BX-U001 for the following Phase 2 study|All-cause mortality|Proportion of patients achieving clinical response by the improvement of at least 2 points on the 7-point ordinal scale.|Duration of ICU stay|Duration of hospital stay|Changes in blood cytokine levels,1,39
859,Serum cholesterol and LDL levels|Tracking the infused cells,1,1
